Review
Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Yi Zhang 1,2,†, Qiong Li 2,†, Zhao Huang 2, Bowen Li 2, Edouard C. Nice 3, Canhua Huang 2, Liuya Wei 4,* and Bingwen Zou 1,*

1 Department of Radiation Oncology, Division of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
2 West China School of Basic Medical Sciences and Forensic Medicine, State Key Laboratory of Biotherapy and Cancer Center, and West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
3 Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia
4 School of Pharmacy, Weifang Medical University, Weifang 261053, China
* Correspondence: weily@wfmc.edu.cn (L.W.); zoubingwen81@163.com (B.Z.)
† These authors contributed equally to this work.

Simple Summary: Reprogramming of glucose metabolism is a hallmark of cancer and can be targeted by therapeutic agents. Some metabolism regulators, such as ivosidenib and enasidenib, have been approved for cancer treatment. Currently, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Furthermore, some natural products have shown efficacy in killing tumor cells by regulating glucose metabolism, offering novel therapeutic opportunities in cancer. However, most of them have failed to be translated into clinical applications due to low selectivity, high toxicity, and side effects. Recent studies suggest that combining glucose metabolism modulators with chemotherapeutic drugs, immunotherapeutic drugs, and other conventional anticancer drugs may be a future direction for cancer treatment.

Abstract: Reprogramming of glucose metabolism provides sufficient energy and raw materials for the proliferation, metastasis, and immune escape of cancer cells, which is enabled by glucose metabolism-related enzymes that are abundantly expressed in a broad range of cancers. Therefore, targeting glucose metabolism enzymes has emerged as a promising strategy for anticancer drug development. Although several glucose metabolism modulators have been approved for cancer treatment in recent years, some limitations exist, such as a short half-life, poor solubility, and numerous adverse effects. With the rapid development of medicinal chemicals, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies have found that some natural products can suppress cancer progression by regulating glucose metabolism enzymes. In this review, we summarize the mechanisms underlying the reprogramming of glucose metabolism and present enzymes that could serve as therapeutic targets. In addition, we systematically review the existing drugs targeting glucose metabolism enzymes, including small-molecule modulators and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeted anticancer drugs are also discussed. In conclusion, combining glucose metabolism modulators with conventional anticancer drugs may be a promising cancer treatment strategy.

Keywords: malignant tumor; glucose metabolism enzymes; glycolysis; targeted therapy

1. Introduction

The primary physiological function of glucose is to serve as a source of carbon and energy for the body’s important activities for meeting the needs of cell growth and proliferation. There are three main glucose energy conversion pathways: aerobic oxidation, anaerobic oxidation (glycolysis), and the pentose phosphate pathway (PPP). Glycolysis
is defined as the breakdown of glucose or glycogen into lactate accompanied by the production of small amounts of adenosine triphosphate (ATP) under hypoxic conditions. Oxidative phosphorylation (OXPHOS) and anaerobic glycolysis are the two major catabolic glucose pathways, in which glycolysis is the common initiation pathway of both [1]. Glucose enters the cell through glucose transferase (GLUT) and produces pyruvate by the functions of three rate-limiting enzymes, hexokinase (HK), phosphofructokinase (PFK), pyruvate kinase (PK), as well as other non-rate-limiting enzymes. Under normal oxygen concentrations, pyruvate enters the mitochondria for oxidative decarboxylation to produce acetyl coenzyme A, followed by complete oxidation by a series of rate-limiting and non-rate-limiting enzymes to produce energy. Briefly, glucose is completely broken down through glycolysis, the tricarboxylic acid cycle (TCA cycle), and OXPHOS (Figure 1A). In the presence of oxygen, one molecule of glucose can yield a net production of 36 to 38 molecules of ATP if processed via this three-stage pathway, the most critical pathway in cellular metabolism. Under anaerobic conditions, pyruvate produced by normal cells through the glycolysis pathway will no longer enter the TCA cycle. However, it produces lactate in the cytoplasm through lactate dehydrogenase (LDH), which produces less ATP.

In the 1920s, Otto Warburg first observed that cancer cells tend to metabolize glucose to lactate even in the presence of sufficient oxygen, known as the Warburg effect or aerobic glycolysis (Figure 1B) [2]. By the 1980s, with the application of fluorodeoxyglucose positron emission tomography (FDG-PET), glucose uptake in clinical tissue samples could be imaged, and the Warburg effect was confirmed in almost all cancers [3–5]. The Warburg effect promotes the glucose uptake of cancer cells in the tumor microenvironment [6]. Further studies have revealed that the tumor growth rate positively correlates with glucose levels and that high glucose levels in cancer patients are associated with poor prognosis [7–9]. Thus, cancer starvation therapy based on glucose deprivation is emerging as an effective treatment for suppressing tumor growth [10–12]. For example, the ketogenic diet can inhibit the metabolic proliferation of cancer cells by reducing blood glucose [13–15]. The Warburg effect is mainly a compensatory activity of cancer cells to adapt to the tumor microenvironment (TME). On one hand, high-efficiency aerobic glycolysis contributes to the proliferation of cancer cells by allowing cancer cells to produce abundant ATP. Although the energy produced by each glucose molecule during aerobic glycolysis is less than that produced by OXPHOS, aerobic glycolysis can generate a number of ATP molecules comparable to OXPHOS when the amount of glucose is sufficient [16]. On the other hand, aerobic glycolysis provides cells with intermediates required for biosynthetic pathways, including ribose for nucleotide synthesis and glycerol, citrate, and nonessential amino acids for lipid synthesis. For example, glucose-6-phosphate (G-6-P) is a substrate for the pentose phosphate pathway that produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate (R-5-P) substrates, and R-5-P is a substrate for nucleic acid synthesis. Additionally, 3-phosphoglyceric acid is the main precursor substrate for serine and glycine synthesis, and serine is involved in one-carbon unit metabolism and is closely related to the production of purines, thymidine, and NADPH [17], which protects cancer cells from damage induced by oxidative stress [2]. Therefore, the Warburg effect is beneficial to the bioenergetics and biosynthesis of cancer cells. In addition, aerobic glycolysis also brings other benefits to cancer cells. For example, a large amount of pyruvate is converted into lactate without entering the TCA cycle to complete OXPHOS during aerobic glycolysis in cancer cells. On one hand, this can reduce the production of reactive oxygen species (ROS) and thus protect mitochondria [2]. On the other hand, long-term maintenance of moderate levels of ROS boosts cancer progression [2]. Meanwhile, glycolysis eventually creates a high-lactate, low-glucose TME. Immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs) [18] and regulatory T (Treg) cells present better tolerance in high-lactate, low-glucose environments. Treg cells can maintain their function by oxidizing lactate [19]. Lactate participates in the homeostatic regulation of M1 macrophages [20] and inhibits CD8+ T cells and natural killer cells (NK cells) from producing γ-interferon [21], which in turn maintains an immunosuppressive microenvironment [22,23]. Overall, metabolic
reprogramming of glucose metabolism, namely the Warburg effect, provides cancer cells with the energy, substrates, and environment required for their survival and contributes significantly to cancer development.

Figure 1. Reprogramming of glucose metabolism in cancer cells. (A) Glucose metabolism in normal cells; (B) glucose metabolism in cancer cells. Cellular uptake of glucose is followed by a series of reactions to transform glucose to pyruvate. Then, glucose enters the TCA cycle or is converted to lactate. Enzymes or pathways predominant in cancer cells are shown in bold red. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; α-KG, α-ketoglutarate; AcCoA, acetyl coenzyme A; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; FAS, fatty acid synthesis; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GCK, glucokinase; GLUT, glucose transporter; glycerol-3P, glycerol-3-phosphate; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; OAA, oxaloacetate; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase 1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; PPP, pentose phosphate pathway; TCA, tricarboxylic acid; TPI, triosephosphate isomerase.

Extensive studies have confirmed that metabolic reprogramming of glucose, which plays a vital role in the proliferation, invasion and metastasis of cancer cells, is closely associated with the survival of cancer cells [24,25]. Therefore, metabolic reprogramming of glucose metabolism is considered the essential hallmark of tumorigenesis and development [26]. Further research found that there are a large number of therapeutic targets for aerobic glycolysis, mainly including key enzymes and transporters. Thus, targeting aerobic glycolysis in cancer cells is a promising therapeutic strategy. Numerous studies have
found that targeted intervention in the aerobic glycolysis of cancer cells can inhibit cancer growth. Several aerobic glycolysis inhibitors are under investigation in preclinical and clinical studies. A few of them, such as ivosidenib and enasidenib, have been successfully translated into clinical applications for cancer treatment [27]. However, toxicity and inferior anticancer efficacy still hinder clinical translation. With the rapid development of chemical technology, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies found that some natural products could suppress cancer progression by regulating glucose metabolism enzymes. Overall, significant progress has been made in recent years in developing anticancer therapeutics targeting metabolic enzymes.

In this review, we briefly introduce normal and reprogrammed glucose metabolism in cancer cells. Furthermore, we focus on enzymes that can serve as therapeutic targets, which may help to develop new anticancer strategies. In addition, this review will present the latest studies on emerging candidate agents targeting glucose metabolism enzymes that could be used in cancer treatment, including small-molecule inhibitors and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeting anticancer drugs are also discussed. This paper aims to highlight the importance of glucose metabolism regulators as valuable tools for developing new anticancer therapies.

2. Drugs That Target Glucose Metabolism Enzymes

To meet the demand for reagents and energy for the rapid and continuous cell proliferation in tumor development and progression, multiple metabolic pathways are changed in tumor cells to promote proliferation, among which abnormal glucose metabolism is the most classic and prominent feature. Therefore, inhibition of abnormal glucose metabolism can inhibit cancer growth. Glucose metabolism enzymes as therapeutic targets may provide a novel perspective and insight for cancer treatment. In the last decade, with the rapid development of medicinal chemistry, several glucose metabolism enzyme inhibitors have been, and continue to be, developed as anticancer drugs. In this section, we review the glucose metabolism enzymes that could serve as therapeutic targets, as shown in Figure 2. Meanwhile, we systematically summarize the current and emerging drugs targeting glucose metabolism enzymes, which may provide fresh ideas for developing anticancer drugs.

2.1. Drugs Targeting Glucose Transferase (GLUT)

Cancer cells consume large amounts of glucose for glycolysis, and glucose enters the cytoplasm through the phospholipid bilayer with the help of GLUT [28]. The GLUT family has 14 members, all of which are capable of selectively transporting different sugar molecules [28]. Among them, GLUT1, GLUT2 (SLC2A2), GLUT3 (SLC2A3), and GLUT4 (SLC2A4) are the four most well-known subtypes, which have distinct regulatory mechanisms and kinetic characteristic and each subtype plays a specific function in maintaining cellular and organismal glucose homeostasis [29,30]. GLUT1 is a widely distributed glucose transporter whose expression is regulated by hypoxia-inducible factor-1α (HIF-1α) [31,32]. GLUT1 has a high affinity for glucose and is highly expressed in a variety of cancers, including lung cancer, prostate cancer, kidney cancer, and lymphoma [33]. In most cancers, a hypoxic TME induces high expression of GLUT1, which enhances the glucose uptake of cancer cells [34]. In addition, high GLUT2 and GLUT3 expression is also simultaneously found in cancer cells [35–37]. Multiple myeloma mainly expresses GLUT4, which is responsible for maintaining adequate glucose uptake [33,38]. The uptake of hexoses, such as fructose and mannose, is also significantly increased in cancers as a result of rapid glucose depletion, with GLUT5 specifically transporting fructose in lymphomas and mannose sharing a transport enzyme with glucose [39,40].
Figure 2. Drugs targeting glucose metabolism in cancer cells. Reprogramming of glucose metabolism provides many potential targets for cancer therapy. Created with BioRender.com (accessed on 22 August 2022). Abbreviations: 1,3 BPG, 1,3-bisphosphoglycerate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; ADP, adenosine diphosphate; ALDO, aldolase; ATP, adenosine triphosphate; DHAP, dihydroxyacetone-phosphate; ENO, enolase; F-1,6-BP, fructose-1,6-bisphosphate; F-2,6-BP, fructose-2,6-bisphosphate; F-6-P, fructose-6-phosphate; G-3-P, glyceraldehyde-3-phosphate; G-6-P, glucose-6-phosphate; HK, hexokinase; LDH, lactate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT, glucose transporter; GPI, glucose-6-phosphate isomerase; MCT, monocarboxylate transporter; PEP, phosphoenolpyruvate; PKF1, phosphofructokinase-1; PFKFB, 6-phosphofructo 2-kinase/fructose-2,6-bisphosphatase; PGAM1, phosphoglycerate mutase 1; PGK1, phosphoglycerate kinase 1; PK, pyruvate kinase; TPI, triosephosphate isomerase.

Cytochalasin B (Figure 3A), a cell-permeable mycotoxin, was the first molecule identified to inhibit GLUT1, which reduces glucose uptake in hepatocellular carcinoma cells [41]. Since then, a series of GLUT inhibitors have been discovered, including synthetic small-molecule inhibitors and natural products. The small-molecule compounds that inhibit GLUT include STF-31, WZB117, BAY-876, and CG-5. Through high-throughput screening, Chan et al. [42] first found that STF-31 (Figure 3B) could inhibit the growth of renal cancer cells by directly binding to GLUT1 to inhibit glucose uptake. However, normal cells do not rely on glycolysis to provide energy and can take up glucose through other isoforms such as GLUT2. Therefore, STF-31 is non-toxic to normal tissues and can selectively kill cancer cells [43,44]. WZB117 (Figure 3C) is a bishydroxybenzoate compound that inhibits the growth of cancer cells by blocking glucose transport through binding to the glucose binding site of GLUT1 [45–48]. Moreover, WZB117 can be used in combination with other anti-cancer drugs, such as paclitaxel or cisplatin, to produce synergistic effects on lung and breast cancer cells [46]. Siebeneicher H et al. [49] screened BAY-876 (Figure 3D) from a compound library using high-throughput screening. BAY-876 inhibited GLUT1 with good metabolic stability in vitro, had a high oral bioavailability in vivo, and its anticancer activity was demonstrated in a variety of cancers, including ovarian and triple-negative breast cancer [50,51]. CG-5 is a thiazolidinedione derivative that inhibits GLUT, blocks glucose transport in T cells, and inhibits glycolysis, thus inhibiting the differentiation of Th1 and Th17 cells, inducing differentiated Treg cells, and suppressing the proliferation of CD4+ T cells [52]. Although the anticancer effects of GLUT inhibitors such as WZB117, BAY876, and CG-5 have been demonstrated in several tumor models, studies on the safety and side effects of these inhibitors are still limited [43,49,53]. With the advancement of technology, novel GLUT inhibitors, such as PUG-1 (Figure 3E) [54], chromopynones (Figure 3F) [55–57], rapaglutin A [35,58], EF24 [39], ketoximes [36], polyphenolic
Several natural products have also been shown to suppress growth in cancer cells by inhibiting GLUT, including phloretin, genistein, fasentin, and apigenin. The polyphenol phloretin (Figure 3G) was shown to inhibit GLUT2 in triple-negative breast cancer, leading to the suppression of cancer growth and metastasis [53]. Additionally, phloretin can inhibit GLUT1, which is overexpressed in the hypoxic area of resistant colon cancer cell lines, and induce apoptosis by activating p53-mediated signaling, leading to suppression of growth in resistant cancer cells [68]. Ji et al. [69] demonstrated that genistein (Figure 3H) could induce apoptosis and inhibit the proliferation of renal cancer cells by increasing CDKN2a expression levels and decreasing methylation, suggesting that genistein is also a potential therapeutic agent for cancer. Moreover, as a GLUT inhibitor, genistein can regulate miR-1260b to affect the Wnt signaling pathway to inhibit cancer tissue growth and metastasis [70]. Fasentin (Figure 3I) and its analogs have been shown to inhibit glucose uptake and decrease resistance to caspase activation, which is involved in the chemoresistance of cancer cells [71–73]. In addition, fasentin resists angiogenesis via glucose-independent metabolism [72]. For most malignant tumors, angiogenesis, a hallmark of cancer, is not only a significant feature but also a drug target [74]. The dual mechanism of fasentin may change the current state of the treatment for malignant tumors [72]. Inhibition of proliferation and apoptosis induction of cancer cells by apigenin (Figure 3J) were associated with the downregulation of GLUT1 expression, which was partly dependent on the inhibition of HIF-1α [31]. Furthermore, apigenin reduced VEGF secretion by cancer cells under both normoxia and hypoxia, suggesting its potential to inhibit cancer metastasis [75–77]. In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezille [88], theophylline [89], (+)-Cryptocaryone [90], and melatonin [91] also have inhibitory effects on GLUT1. Moreover, natural product compounds generally have better safety and less toxicity in comparison to synthetic drugs. For example, Baeckea frutescens leaf extracts could inhibit GLUT, blocking glucose transport in T cells, and inhibiting glycolysis, thus inhibiting the differentiation of Th1 and Th17 cells, inducing differentiated Treg cells, and suppressing the growth of cancer cells by blocking glucose transport through binding to the GLUT isoform [31].

**Figure 3.** The chemical structures of drugs targeting glucose transferase.
inhibit tumor growth by reducing glucose uptake in breast cancer cells, but there was no obvious cytotoxic effect on normal cells [92]. However, various natural products usually have the limitations of low stability and solubility in the physiological environment and low delivery efficiency due to multi-targeting and low site-specific distribution in the lesion. Thus, drug delivery systems have been designed to improve those disadvantages, such as liposomes, inorganic metal frames, and hydrogels [93–95]. Computational modeling and computer-aided drug design have contributed immensely to the successful development of drugs, especially in the contemporary pharmaceutical and drug industries. Integrating computer-aided drug design (CADD) into the development of GLUT has contributed to the enhancement of selective drug targeting with reduced toxicity and off-target effects [96–98]. However, few studies exist directly comparing the efficacy and safety of synthetic chemicals against natural substances for targeting glucose transferase (GLUT). We expect that these issues will attract more attention and contribute to intensive research.

In conclusion, GLUT inhibitors demonstrate the potential value of glucose transferase as targets for cancer therapy. Exploring their mechanisms can help to better understand the process of cancer development and progression and develop corresponding targeted drugs. However, the widespread expression of GLUTs in normal cells limits the application of such drugs. Therefore, developing highly selective inhibitors of GLUT to avoid the side effects caused by inhibition of other isoforms is a central challenge in the development of this drug. In addition, the combination of GLUT inhibitors with GLUT signaling pathway inhibitors (e.g., Akt, mTOR, PI3K, HIF-1α, and AMPK) could be a new direction for cancer therapy.

2.2. Drugs Targeting Hexokinase (HK)

The first rate-limiting enzyme of glycolysis is HK, which catalyzes the conversion of glucose to glucose-6-phosphate (G-6-P). Since G-6-P is a common intermediate product of glycolysis, PPP, and glycogen synthesis, this process is considered to be the most critical step in the process of glucose metabolism, and HK is regarded as the most important rate-limiting enzyme. There are four isoforms of mammalian HK named HK1, HK2, HK3, and HK4. HK1, HK2, and HK3 are high-affinity HKs, and HK1 and HK2 can specifically bind in mitochondria to voltage-dependent anion channels (VDACs), known as mitochondrial porins [99]. The autocatalytic product G-6-P mediates feedback inhibition of HK1, HK2, and HK3 activity, and G-6-P induces conformational changes in HK1 and HK2 that separate them from the mitochondria [99,100]. By binding to the outer mitochondrial membrane and VDAC, HK1 and HK2 preferentially dephosphorylate glucose using mitochondria-derived ATP, thereby linking OXPHOS and glycolysis [101]. HK1 is widely expressed in numerous organs, and HK2 expression is significantly upregulated in cancer cells, promoting glucose uptake and participation in multiple metabolic pathways [101]. Therefore, the high HK activity in cancer cells mainly results from the induced expression of HK2 [101]. In addition, p53 family members (p53, p63, and p73) play a significant role in regulating HK2 [102]. p53 can bind to the HK2 gene promoter, thus suppressing HK2 transcriptional activity and regulating its expression [103,104]. p63 and p73 are homologs of p53 and share some common functions with p53 [105,106]. However, p63 and p73 are more complex in structure, containing two major isoforms of each protein (TAp63, ΔNp63, TAp73, and ΔNp73). Similar to p53, TAp63 and TAp73 can inhibit glycolysis by inhibiting HK2 [107]. Contrary to TAp63, ΔNp63 was shown to upregulate the expression of HK2 [107,108]. Furthermore, the high expression of HK2 in cancer tissue cells is directly related to DNA methylation [100]. Overall, the elevated expression of HK2 causes significantly more efficient glycolysis in malignant tumors than in normal cells, which promotes the proliferation of cancer cells. HK2 is barely expressed in normal cells; therefore, its systematic knockdown selectively targets cancer cells [109]. Further studies revealed that germline knockdown of HK2 results in embryonic death, but systemic knockdown of HK2 in adult mice did not affect their survival. In addition, knockdown of HK2 was found to inhibit cancer development in mouse models and, more importantly, did not activate HK1 expression [109]. Several studies have shown that systemic inhibition of HK2 can safely and effectively block cancer growth [100,110–112].
However, due to the high structural similarity of HK1 and HK2 [113,114], the development of specific inhibitors remains a great challenge. Many HK inhibitors have been exploited for anticancer effects. Among them, 2-deoxy-d-glucose (2-DG), lonidamine (LN), and 3-bromopyruvate (3-BrPA) have been the most studied. These molecules all target HK2 in many in vitro and in vivo tumor models, detach it from mitochondria, and elicit cancer cell death [112]. 2-DG (Figure 4A) is a glycolysis inhibitor that targets HK2 and competes with glucose for HK to inhibit glycolysis [115]. Preclinical studies have demonstrated that 2-DG significantly inhibits glycolysis and ATP synthesis [115]. Despite the promising results of 2-DG in preclinical studies, the results of clinical trials have been inconsistent [116–118]. Currently, 2-DG has been reintroduced for use in combination approaches, using 2-DG to produce synergistic anticancer effects with other anticancer agents [119,120]. In several clinical studies, 2-DG has been used as an adjuvant to clinical chemotherapeutic agents for various cancers, including breast, prostate, ovarian, lung, and glioma [121–123]. However, the use of 2-DG in cancer therapy is still limited. Studies have shown that the plasma half-life of 2-DG is only 48 min, and 2-DG must be administered at a relatively high concentration (5 mmol/L) to compete with blood glucose [121]. However, high doses of 2-DG can lead to adverse effects such as fatigue, sweating, dizziness, nausea, and hypoglycemia [123]. LN (Figure 4B) was previously used as an antispermgerm agent, but now it is known to have anticancer and proapoptotic effects [124]. LN is an adenine nucleotide translocator (ANT) ligand that induces mitochondrial channel formation and inhibits complex I and complex II [125]. As an emerging glucose metabolism enzyme-targeted drug, LN can be used alone or in combination with other anticancer agents. This agent has entered clinical trials for cancer treatment [126], such as lung, breast, and ovarian cancer [127–130]. Nevertheless, significant pancreatic and hepatic toxicities have limited LN’s clinical success [131]. Combination therapy studies revealed that combination with other chemotherapeutics, such as doxorubicin, produced better anticancer effects for the treatment of breast, prostate, and ovarian cancers [132,133]. To reduce LN toxicity, current research has focused on developing alternative dosage forms or local targeted delivery of LN. Nanomedicines for LN have been shown to inhibit glucose metabolism in cancer cells and regulate the immunosuppressive microenvironment, indicating great promise for the development of nanomedicines targeting glycolysis [134]. 3-BrPA (Figure 4C) is another HK2 inhibitor that can directly inhibit HK2 activity, thereby strongly inhibiting glycolysis [135]. 3-BrPA has been shown to enhance the cytotoxic effect and decrease resistance to other anticancer drugs by inhibiting the ATP-dependent multiple drug resistance (MDR) transporter, providing a promising candidate in combination therapy [136,137]. Regrettably, these molecules inhibit all HKs with less specificity for HK2, with the evident risk of suppressing glucose phosphorylation and utilization in crucial normal organs. Therefore, improving the pharmacokinetic properties of HK inhibitors, prolonging the half-life of the drug, synthesizing novel analogs or prodrugs of HK inhibitors, and enhancing the targeting of such drugs to cancer cells in vivo to reduce the occurrence of adverse effects may be essential strategies to break the limits of clinical application.

Many new HK inhibitors have been identified in recent years. For example, metformin can reduce mTORC1 activity in HCC cells, inhibiting protein synthesis and inducing cancer cell death in the absence of HK2 expression [112]. Several flavone derivatives, including oroxylin A (Figure 4D), chrysin (Figure 4E) [112], amentoflavone (AF) (Figure 4F) [138], Gen-27 (Figure 4G) [139,140], and GL-V9 (Figure 4H) [138], have shown anticancer effects targeting HK2. Specifically, oroxylin A reduces HK2 expression and inhibits the binding of HK2 to mitochondrial VDAC, which is dependent on the deacetylation of procyclin D by SIRT3 [141]. Similarly, methyl jasmonate (MJ) (Figure 4I) can also inhibit HK2 expression and suppress HK2 and VDAC binding [142–144]. However, the selectivity of MJ to HK2 in cancers is relatively poor. Novel HK2 inhibitors, such as benserazide (Figure 4J) [145] and benitrobenrazide (Figure 4K) [146], have also shown effects in cancer therapy. However, the relevant studies are limited and further exploration is needed.
Many natural products or natural compounds, such as arsenic trioxide (ATO), curcumin, and epigallocatechin gallate (EGCG), have also been shown to inhibit HK2, suppressing growth and inducing apoptosis in cancer cells. Arsenic trioxide (ATO) (Figure 4L) is the main active ingredient of the traditional Chinese medicine (TCM) arsenic, which can inhibit the growth of gastric cancer by regulating glucose metabolism through down-regulation of HK2 expression [147]. Curcumin also inhibits colorectal cancer growth by downregulating HK2 expression [148]. Epigallocatechin gallate (EGCG) dose-dependently inhibits the anchorage-independent growth of human tongue squamous cell carcinoma. It reduces HK2 protein expression by inhibiting the AKT pathway to suppress glycolysis and inhibits HK2 binding to mitochondria to promote apoptosis [149]. Dai et al. [150] found that resveratrol inhibited glycolysis and induced apoptosis in hepatocellular carcinoma cells by inhibiting HK2 expression to activate mitochondria-associated apoptotic signaling, and that it could also enhance the antihepatocarcinogenic effect of sorafenib. In addition, natural products or natural compounds such as bufalin (Figure 4M) [151], cryptotanshinone (Figure 4N) [152], resveratrol (Figure 4O) [153], shikonin [154], fenofibrate [155], halofuginone [156], licochalcone A [157], jolkinolide B [158], ginsenoside 20(S)-Rg3 [159], ketoconazole [160], posaconazole [160], and astragalin [161] have also exhibited inhibitory effects on HK2.

2.3. Drugs Targeting Phosphofructokinase (PFK)

The second rate-limiting enzyme of glycolysis is PFK, which catalyzes the conversion of fructose-6-phosphate (F-6-P) to fructose-1,6-bisphosphate (F-2,6-BP). PFK is allosterically activated by adenosine monophosphate (AMP) and F-2,6-BP. PFK can be inhibited by the elevated F-2,6-BP level to sustain cancer cell growth [162]. F-2,6-BP, a product of the reaction catalyzed by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2/FBFase-2, PFKFB), is the most potent positive allosteric effector of PFK1 [163]. PFK2/FBFase-2 is a bifunctional enzyme responsible for the catalysis of both the synthesis and degradation of F-2,6-BP mediated through its N-terminal domain (2-Kase) and C-terminal domain (2-Pase), respectively [164]. In other words, PFKFB is an enzyme with both kinase and phosphatase activities, and the level of F-2,6-BP depends on the relative activities of kinase and phosphatase. Therefore, inhibiting the kinase activity of PFKFB while maintaining its
phosphatase activity can inhibit PFK1 activity by reducing F-2,6-BP levels to block cancer growth [165]. In addition, PFKFB3 is commonly overexpressed in breast, colon, ovarian, and thyroid cancers but is expressed at low levels in normal tissues and is the basis of targeted therapy for a variety of cancers [166]. It was also found that inhibiting PFKFB3 could suppress pathological angiogenesis without affecting normal blood vessels.

PFK is controlled by a family of bifunctional enzymes, including PFKFBs [167]. PFKFB3 is overexpressed in various cancers, including breast, colon, nasopharyngeal, pancreatic, and gastric cancers, and is associated with lymph node metastasis and survival [168]. A large number of inhibitors of PFKFB3 have been reported, including 3PO (Figure 5A) [169,170], PFK15 (Figure 5B) [171], PFK158 (Figure 5C) [172,173], YN1 (Figure 5D) [174], and N4A (Figure 5E) [174]. In contrast to 2-DG, which can cause serious toxicity and systemic adverse effects, 3PO only partially and transiently reduces glycolysis without causing serious toxicity to normal tissues. Administration of 3PO was shown to produce a rapid reduction in glucose uptake, lactate production, and ATP generation in Jurkat T-cell leukemia cells [170]. PFK15, a derivative of 3PO, exhibits approximately a 100-fold increase in PFKFB3 inhibitory activity when compared to 3PO. PFK15 has been reported to exhibit significant anticancer activity by reducing 18FDG uptake and F-2,6-BP levels in xenografted tumors. Moreover, PFK15 exhibits a proapoptotic effect in transformed cancer cells in vivo and in vitro [171]. Several studies have demonstrated the ability of PFK15 and PFK158 to synergize with targeted and chemotherapeutic agents [173,175,176]. In addition, it has also been shown that PFK15 increases the sensitivity of chronic granulocytic leukemia cells to imatinib and enhances the cytotoxicity of oxaliplatin against colorectal cancers [177,178]. The combination of CTLA-4 antibody and PFK158 can significantly enhance the inhibition of cancer growth, showing a bright future for immunotherapy combined with targeted glucose metabolism therapy [179]. Some studies have found that PFKFB3 plays a key role in the repair of DNA damage by homologous recombination, leading to the development of the small-molecule PFKFB3 inhibitor KAN0438757 (Figure 5F), suggesting that PFKFB3 may play a key role in the initiation and development of malignant tumors [180]. Moreover, compounds such as BrAcNHEtOP (Figure 5G) [167], YZ9 (Figure 5H) [167], PQP (Figure 5I) [181], KAN0436151 (Figure 5J), benzindoles [182], and salicylic acid sulfonamides [183] have also been found to have pharmacological effects on PFK inhibition.

![Figure 5](image-url)  
**Figure 5.** The chemical structures of drugs targeting phosphofructokinase.
2.4. Drugs Targeting Pyruvate Kinase (PK)

The third rate-limiting step in glycolysis is pyruvate kinase (PK), which catalyzes the dephosphorylation of phosphoenolpyruvate to produce enolpyruvate. In mammalian cells, there are four main isoforms of PK: PKM1, PKM2, PKR, and PKL. PKL and PKR are mainly expressed in the liver and erythrocytes, respectively, and PKM1 is highly expressed in muscle and brain tissues. In cancer cells, low-affinity PKM2 is the main isoform. Further research has found that PKM2 exists in different forms, and in cancers, it mostly exists as a low-activity dimer, a form that is more likely to promote cancer growth [184]. In addition, PKM2 can exert its effects through post-translational modifications, including phosphorylation [185], O-acetylgulosamine (O-GlcNAc) modification [186], acetylation [187], succinylation [188] and methylation [189]. Numerous studies have shown that inhibition of PKM2 can improve the sensitivity of cancer cells to chemotherapeutic drugs such as cisplatin and reverse drug resistance [190,191]. Interestingly, either the inhibition or activation of PKM2 inhibited the growth of cancer cells, which may be related to the response of cancer cells to different degrees of hypoxia [192,193].

There are three main types of PKM2 inhibitors that have been identified: shikonin, metformin, and vitamin K. Shikonin (Figure 6A), the active ingredient extracted from the plant comfrey, is the most potent and specific PKM2 inhibitor reported to date. Shikonin’s analog, alkannin, also shows potential anticancer therapeutic value in targeting PKM2 [194]. Shikonin reduces platinum resistance in human colorectal and advanced bladder cancer cells by inhibiting PKM2 activity and reverses cisplatin resistance in cervical cancer cells in a dose-dependent manner [194]. In addition, shikonin significantly reduced gefitinib resistance in lung cancer cells and inhibited the development and metastasis of esophageal and bladder cancers [195,196]. However, due to shikonin’s poor solubility and complex pharmacological activity [197], there are still many safety concerns for its direct incorporation into treatment protocols. Therefore, optimizing the drug structure to target and enhance anticancer activity, utilizing nanoformulations, and other methods to enhance drug solubility are ways to overcome these limitations. In the past decade, various advanced drug delivery systems have been widely reported, including nanoparticles [198,199], liposomes [200–202], microcapsules [203], electrospun nanofibres [204], microemulsions [205], microneedles [206], polymeric micelles [207], etc. These nano-delivery systems transcend the limitations of conventional carrier systems and facilitate the precise delivery of shikonin and its derivatives to the target site of action [208–210]. Metformin (Figure 6B) is a commonly recommended drug for type II diabetes mellitus, but several studies have shown that metformin also has high potential as an anticancer agent [211]. Metformin enhanced the sensitivity of osteosarcoma stem cells to cisplatin by decreasing the expression level of PKM2 and inhibited glucose uptake, lactate production, and ATP production in osteosarcoma stem cells [212]. In addition, the combination of metformin and anti-ENO1 antibody significantly reduced the resistance of human non-small cell lung cancer cells to cetuximab and activated AMPK to downregulate PKM2 to inhibit metastasis and invasion of kidney cancer cells [213]. However, metformin is not highly selective for PKM2, and its pharmacological effects and clinical applications in other fields are very complicated. Therefore, the clinical use of metformin for cancer therapy needs further exploration. Vitamin K (VK) is a fat-soluble naphthoquinone, of which the VK3 (Figure 6C) and VK5 (Figure 6D) isoforms can inhibit PKM2 with an inhibitory effect that is more significant than that of PKM1 [214]. Studies have shown that the combination of VK3 and vitamin C (VC) can improve the therapeutic effect [215] and clinical trials have shown that VK3 can reverse cellular resistance to doxorubicin and Adriamycin [216]. However, the clinical use of VK as an adjuvant for reversal of drug resistance is limited, which may be related to the contraindication of the use of VK for hepatic dysfunction, as patients with cancers treated with long-term chemotherapy are prone to impaired liver function or hepatic dysfunction, which essentially limits the application of VK in anticancer therapy. Zhou Y et al. [217] recently discovered that benserazide (Figure 6J), a dopa decarboxylase inhibitor for Parkinson’s disease, was also able to specifically bind and block PKM2 enzyme activity and
inhibit glycolysis, which inhibited the growth of melanoma. Such discoveries provide additional ideas for drug combinations for the treatment of cancers. In addition, several compounds, such as lapachol (Figure 6E) [218], C3k (Figure 6F) [219], benzoxepane derivatives (Figure 6G) [220], cyclosporin A (CsA), tannic acid (TA), and beta-elemene and can inhibit PKM2, leading to the suppression of glycolysis in cancer cells.

Figure 6. The chemical structures of drugs targeting pyruvate kinase.

Several natural products or natural compounds have also been shown to inhibit HK2. For example, Liu et al. [221] found that olea nolic acid (OA) induced the conversion of PKM2 to PKM1 and attenuated the Warburg effect, suggesting that OA is a compound that inhibits aerobic glycolysis. MC-4, an extract from Artemisia annua, reduced the expression of PKM2 and GLUT1 and significantly inhibited cancer growth [222]. Further research found that the combination of MC-4 and everolimus can synergistically exert anticancer effects through AKT/PKM2 and mTOR to inhibit cancer growth and metastasis, which provides a theoretical basis for the combination of targeted therapy with glycolysis inhibitors [222]. In addition, many natural products or natural compounds, such as curcumin [223,224], resveratrol [225,226], proanthocyanidin B2 (PB2) (Figure 6H) [227], apigenin, wogonin, chysin, and many more [228,229] are also able to bind to the variable site of PKM2 and inhibit glycolysis.

As mentioned earlier, most PKM2 in cancer tissues are low-activity dimers, which catalyze relatively less pyruvate production, thus providing sufficient intermediate components for conversion into proteins, nucleotides, and other vital substances necessary for cancer cell proliferation [229]. In a breast cancer model, knockdown of PKM2 can enhance tumor formation, suggesting that PKM2 inhibition alone may not be effective [230]. TEPP-46 and DASA-58, both PKM2 activators, significantly increased the level of highly active PKM2 tetramers, which hindered tumorigenesis in animal experiments, inhibited the metabolism of nucleotides and serine and reduced lactate production [231]. Mohammad et al. [232] found that the use of TEPP-46 significantly enhanced PK activity in pancreatic cancer cells, downregulated PKM2 dimer expression, and inhibited the growth of tumors in a mouse model. In addition, many molecules, such as parthenolide (PTL 5) (Figure 6I) [233], ML-265 (Figure 6K) [234], PA-12 [235], Pyridin-3-ylmethyl carbamothioic esters [236], ZINC08383544 [237], and compound 0089-0022 [238], inhibit tumor growth as PKM2 ag-
onists. Some researchers have also explored the effects of herbal components on PKM2 enzyme activity. Aslan et al. [239] found that polyphenolic extracts such as prunetinone and quercetin flavonoids have efficient activating effects on PKM2 enzyme activity. Mustard acid and p-coumaric acid can also act as PKM2 activators for anticancer effects [239].

Although many studies have been conducted on inhibitors and activators targeting PKM2, their specific applications have not been fully explored. For example, in individualized cancer therapy, it is worthwhile to investigate which types of cancer and at which stage of cancer the inhibitors and activators should be used. With development and research of activators and inhibitors with high specificity, drugs targeting PKM2 will become more widely used in cancer treatment.

2.5. Drugs Targeting Lactate Dehydrogenase (LDH)

Lactate dehydrogenase (LDH) catalyzes the last step in the glucose metabolism process, catalyzing the reversible conversion of pyruvate to lactate. The accumulation of lactate affects the pH in the TME. As a proinflammatory and immunosuppressive mediator, lactate promotes the malignant progression of tumors. Studies have shown that high levels of lactate are associated with early distant metastasis of cancer [240]. Lactate also activates matrix metalloproteinase (MMP) histone proteases; upregulates vascular endothelial growth factor (VEGF), HIF-1α, and transforming growth factor-β2 (TGF-β2); and directly enhances the migration ability of cells [241]. The human genome has four LDH genes: LDHA, LDHB, LDHC, and LDHD. LDHA and LDHB are highly expressed in cancers [242], with LDHA responsible for converting pyruvate to lactate and LDHB responsible for converting lactate to pyruvate. The predominant isoform in cancers is LDHA [23]. High LDHA expression is related to the poor prognosis of malignant tumors [243,244]. In addition, LDHA can also promote lactate production, thereby remodeling the TME and suppressing the immune system to promote immune escape [23,65]. Furthermore, it was found that upregulation of LDHA ensures efficient aerobic glycolysis in cancer cells, but the enzyme is not required for healthy cells under normal conditions [245]. Knockdown of LDHA can inhibit cancer cell proliferation, suggesting that targeting LDHA is a promising strategy to inhibit the growth of malignant tumors. In addition, knockdown of LDHA can also have an effect on matrix metalloproteinases, thus affecting cancer cell invasion and metastasis [246]. Therefore, the main target for developing anticancer drugs against LDH is LDHA.

There is currently much research devoted to the search for selective inhibitors of LDHA [23]. The natural compound gossypol (Figure 7A), a nonselective LDHA inhibitor, has shown efficient anticancer activity in vitro and in preclinical experiments, but gossypol also interacts with other components in the cell involving multiple biological functions, leading to nonspecific toxicities [247]. Therefore, there is a need to design chemically synthesized LDHA inhibitors to improve the efficiency and safety of these drugs. FXII (Figure 7B), a catechol-containing small compound that inhibits LDHA, was shown to inhibit tumor growth in xenografts [248]. In lymphoma and pancreatic cancer, FX-11 can reduce cellular lactate production, induce oxidative stress, and ultimately lead to apoptosis and the inhibition of cancer progression [248]. In prostate cancer, FX-11 as a single agent was also shown to be effective in inhibiting the glycolysis of cancer cells and consequently the growth of cancer cells [248]. In addition, galloflavin (Figure 7C) has been reported to bind to free LDHA and inhibit glycolysis in breast cancer cells, which inhibits cancer growth [249]. Oxamate (Figure 7D) is a competitive LDH inhibitor that exerts its pharmacological effects by competing with the LDHA substrate pyruvate. When combined with LDHA, oxamate can inhibit the conversion of pyruvate to lactate by inhibiting LDH and inhibiting the proliferation and migration of prostate and breast cancer [250–252], and its sensitivity can be effectively improved when combined with temozolomide [253]. However, in vitro studies have shown that oxalate requires concentrations above the millimolar level to exert anticancer effects. Notably, oxidative cancer cells are less sensitive to LDHA inhibitors, while some glycolytic cancer cells will compensate for the inhibition of glycolysis by OXPHOS and become resistant to LDHA inhibitors. Therefore, LDHA inhibitors can
be used in combination with OXPHOS inhibitors (e.g., phenylephrine) to exert a more comprehensive anticancer effect [254]. In addition, morin (Figure 7E), EGCG (Figure 7F), the NADH competitive inhibitor GSK2837808A [255], pyruvate and NADH competitive inhibitors NHI1 and NHI2 [256], metamorphic inhibitor PSTMB [257], and piperidine derivative GNE140 [258] all have strong inhibitory and selective effects on LDHA and can inhibit cancer progression with less effect on normal cells, and are therefore considered as potential novel anticancer drugs [259].

![Chemical structures of drugs targeting lactate dehydrogenase.](image_url)

**Figure 7.** The chemical structures of drugs targeting lactate dehydrogenase.

### 2.6. Drugs Targeting Aldolase (ALDO)

Aldolase (ALDO) catalyzes the breakdown of F-1,6-BP to dihydroxyacetone phosphate and glyceraldehyde-3-phosphate in a reversible reaction. ALDO can bind to actin fibers, and the PI3K signaling pathway allows ALDO to separate from actin fibers and promote glycolysis [260]. ALDOA expression is significantly increased in HCC tissues and is associated with the malignant progression of HCC [261]. On the other hand, dietary restriction (DR) can upregulate the ALDOA/DNA-PK/p53 pathway, a potential mechanism for the anticancer effect of DR [262]. TDZD-8, a small molecule metamorphic inhibitor, has been found to specifically target the Cys289 site of ALDOA, inhibit the glycolytic function of ALDOA, and reduce the stability of HIF-1α to exert anticancer effects [263]. In addition, Chang et al. [264] found that raltegravir suppresses lung cancer metastasis by inhibiting ALDOA–γ-actin interactions and was not significantly toxic to normal lung tissue. However, this was limited to laboratory studies, and raltegravir is mainly useful in antiviral therapy, so the therapeutic role of raltegravir in tumors needs to be further explored.

### 2.7. Drugs Targeting Phosphoglycerate Kinase 1 (PGK1)

Another key enzyme in glycolysis is phosphoglycerate kinase 1 (PGK1). In non-small cell lung cancer cells, the long noncoding RNA MetaLnc9 interacts with the glycolytic kinase PGK1. It prevents ubiquitination, which activates the oncogenic AKT/mTOR signaling pathway and accelerates cancer progression [265]. Overexpression of the proto-oncogene gankyrin attenuates cellular oxidative stress and increases the oncogenic properties of gastric cancer cells through activation of the PGK1/AKT/mTOR pathway [266]. However, since there is a lack of promising lead compounds, studies on PGK1 inhibitors are comparatively weak [267]. Moreover, the effects of existing PGK1 inhibitors such as CBR-470-1, bisphosphonates, terazosin, and their derivatives on cancer cells have not been reported [268].
2.8. Drugs Targeting Phosphoglycerate Mutase 1 (PGAM1)

Phosphoglycerate mutase 1 (PGAM1), which is regulated by TP53, is commonly up-regulated in human cancers and promotes cancer cell proliferation and cancer growth by regulating the levels of its substrate 3-PG and product 2-PG [269]. Moreover, the expression level of PGAM1 was negatively correlated with the prognosis of cancer patients and positively correlated with tumor stage and pathological grade in HCC [270], bladder cancer [271], and lung cancer [272]. Therefore, PGAM1 is a promising target for antitumor drugs. Evans et al. [273] first reported the small molecule compound MJE3, which can specifically act on PGAM1 and inhibit the proliferation of breast cancer cells. Hitosugi et al. [274] identified three compounds through in vitro screening and obtained PGMI-004 after structural optimization; it can selectively inhibit PGAM1 activity, significantly inhibit glycolysis and PP in cancer cells, and reduce the synthesis of biomolecules such as nucleotides, amino acids, and lipids, while being less toxic to normal cells.

2.9. Drugs Targeting Enolase (ENO)

Enolase (ENO) catalyzes the reversible reaction of phosphoenolpyruvate production and is highly expressed in nasopharyngeal carcinoma and non-small cell lung cancer. ENO can promote cell proliferation, migration, and invasion by upregulating glycolysis through activation of the PI3K/AKT pathway [275]. The expression of ENO1 is elevated in several cancer tissues, suggesting its close association with carcinogenesis. According to Yin H et al. [276], ENO1 overexpression in pancreatic cancer is associated with clinical stage, lymph node metastasis, and poor prognosis. ENO1 also promotes cisplatin resistance in patients with gastric cancer [277]. Chemical enolase inhibitors include sodium fluoride, D-tartarate, and 3-aminoenolpyruvate 2-phosphate, but none of these are appropriate for cancer therapy [278,279]. Phosphonoacetohydroxamicacid (PhAH), a pan-enolase transition-state analogue inhibitor, can inhibit both enzymatic activity and proliferation in cancer cells, including pancreatic, breast, and lung cancers [280,281]. In addition, ENOblock (AP-III-a4) has also been found to have anticancer effects [282]. Overall, concerted efforts are still required to develop suitable drugs that do not affect normal cells.

2.10. Drugs Targeting Monocarboxylate Transporters (MCTs)

In addition to the above glucose metabolism enzymes, monocarboxylate transporters (MCTs) are also functional molecules essential for the glycolytic process and play a vital role in the growth of cancer cells. MCTs are responsible for transporting lactate produced by glycolysis to the extracellular compartment, preventing excessive acidification of the cytoplasm, and protecting cells from damage caused by the acidic environment. MCT overexpression in cancer cells can maintain the appropriate pH for cancer growth, thus promoting proliferation [283]. AstraZeneca developed AZD3965, a selective inhibitor of MCT1 which was shown to inhibit the bidirectional transport of lactate in cancers. AZD3965 caused an increase in intracellular lactate content and a decrease in ATP, which in combination with radiotherapy reduced cancer growth and prolonged survival, enhancing radiotherapy sensitivity [284]. A recent study found that the MCT inhibitor AZD3965 also inhibits lipid biosynthesis and increases tumor immune cell infiltration involving dendritic cells (DCs) and NK cells in the TME [285]. AZD3965 in combination with an anti-PD-1 antibody reverses the immunosuppressive microenvironment of solid tumors by targeting MCT1.

A nanodrug composed of an MCT1 inhibitor (AZD3965) loaded inside the ultra-pH-sensitive nanoparticles (AZD-UPS NPs) can reduce the dose of AZD3965 and can increase the effect of immunotherapy [286]. AZ93 has been reported to selectively inhibit MCT4 and has been used in preclinical studies [287]. More compounds that can effectively reduce lactate flux are 7-aminocarboxycoumarins (7ACCs). 7ACCs retard the growth of a variety of cancer cells, and 7ACCs inhibit the recurrence of cervical cancer after cisplatin treatment [288]. In addition, MCT inhibitors such as AR-C155858 [289] and VB124 [290] have also been found to have an anticancer effect.
2.11. Drugs Targeting Isocitrate Dehydrogenase (IDH)

IDH is a family of metabolic enzymes with important roles in the TAC cycle that is widely involved in glucose metabolism, amino acid metabolism, and lipid metabolism [291]. The main role of IDH is to catalyze the oxidative decarboxylation of isocitrate to generate α-ketoglutarate (α-KG), while reducing nicotinamide adenine dinucleotide (NAD⁺) and beta-nicotinamide adenine dinucleotide phosphoric acid (NADP⁺) to the reduced form of nicotinamide adenine dinucleotide (NADH) and the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH). IDH1/2 mutations promote the development of various cancers, such as lymphoma and glioma; ivosidenib, which targets mutated IDH1, and enasidenib, which targets IDH2, were approved for marketing and use in the treatment of acute myeloid leukemia in 2017 and 2018, respectively [292–294]. Moreover, other compounds, such as IDH305 and AG-881, have been in clinical trials [295].

3. Combinational Strategies Using Glucose Metabolism Enzyme Inhibitors

Despite the rapid development of various small-molecule inhibitors of glucose metabolism enzymes, their clinical applications are still limited. Combination with other anticancer drugs may show enhanced anticancer effects. For example, the combination of PKM2 activators and LDHA inhibitors significantly reduced cancer growth in a mouse model of pancreatic adenocarcinoma transplantation, suggesting the potential value of multitarget glycolytic inhibitors in combination [232]. In addition, treatment with drugs targeting glucose metabolism enzymes will cause a compensatory enhancement in the metabolism of other nutrients in cancer cells [254]. For example, significantly elevated levels of redox reactions were found in various cancer cells after glycolysis was inhibited [296,297]. This problem can be solved by combining a glucose metabolism enzyme inhibitor with an OXPHOS inhibitor [254,298].

In addition, increasing evidence suggests that aerobic glycolysis not only promotes cancer cell proliferation but is also associated with chemotherapy resistance. Therefore, drugs targeting glycolysis may provide additional killing capacity for chemotherapy. For example, Korga et al. [299] used 2-DG in combination with adriamycin to treat liver cancer cells. The results showed that the combination therapy was more effective in inhibiting liver cancer cell activity and promoting apoptosis than adriamycin treatment alone. Further studies revealed that 2-DG inhibited protein N-glycosylation and improved the efficacy of standard chemotherapy through chemo-sensitization and reversing resistance to 5-fluorouracil (5-FU) in prostate cancer cells, trastuzumab in breast cancer cells, and Bcl-2 inhibitors in leukemia cells [300,301]. The use of 2-DG also significantly reduced resistance to paclitaxel and adriamycin in osteosarcoma and non-small cell lung cancer transplanted mice when compared with chemotherapy alone [302]. 2-DG combined with sorafenib and 2-aminophenoxazine-3-one (Phx-3) also enhanced the anticancer effect of 2-DG in hepatocellular carcinoma [115,303]. The GLUT1 inhibitor BAY876 was found to enhance cisplatin-mediated antiproliferative effects in laryngeal squamous carcinoma [304]. This suggests that glycolysis inhibitors can enhance the sensitivity of cancer cells to chemotherapeutic drugs. The mechanism by which this occurs seems to be that glycolysis inhibitors deprive the energy supply of cancer cells, thus reducing the resistance of cancer cells to chemotherapeutic drugs. In conclusion, combining chemotherapeutic agents and glycolysis inhibitors is a promising strategy for the treatment of cancer.

A negative correlation was found between glucose metabolism enrichment scores and immune cell activity in triple-negative breast cancer. It is suggested that combining PD-1 or PD-L1 antibodies with glycolytic inhibitors is a promising therapeutic strategy. The combination of a PD-1 inhibitor and LDH inhibitor FX11 significantly increased tumor CD8⁺ and NK cells infiltration and demonstrated remarkable anticancer effects [305]. Zappasodi et al. [306] found that knockdown of LDH and blockade of CTLA-4 in a high glycolytic mouse breast cancer tumor model promoted immune cell infiltration and Treg cells were forced to participate in glycolysis in the presence of glucose, enhancing glucose uptake and IFN-γ production, leading to a loss of Treg cell stability. Blocking CTLA-4 is
more suitable for treating cancers with low levels of glycolysis, while for cancers with high levels of glycolysis, the combination of anti-CTLA-4 antibodies with glycolysis inhibitors increases the availability of glucose in the TME, which maximizes Treg cell instability and enhances anticancer immunity [306]. Of note, diclofenac reduced lactate secretion and enhanced the killing ability of infiltrating T cells in in vitro experiments [307]. Diclofenac has previously been shown to be an MCT1/4 inhibitor, and studies support the concept of combining glycolytic inhibitors and immune checkpoint inhibitors in clinical trials for the treatment of highly glycolytic cancers. Ho et al. [308] found that tumor-infiltrating T cells compete with cancer cells for metabolism in the TME. Reducing the glucose level in the TME can inhibit the response of infiltrating T cells against cancer cells. In addition, T cells express PD-1 on their surface, while cancer cells express the PD-L1 on their surface, which can escape T-cell immune surveillance. A recent study [290] found that the combination of MCT inhibitors and PD-1 monoclonal antibodies reduced the growth of transplanted tumors and increased the infiltration of CD8+ T cells in murine hepatocellular carcinoma and was able to significantly enhance the anticancer effects of anti-PD-1 antibodies. The above studies indicate a bright future for the combination of immune checkpoint inhibitors and glycolysis inhibitors.

4. Limitations of Drugs Targeting Glucose Metabolism Enzymes

Although preclinical studies have demonstrated the effectiveness of glucose metabolism enzyme-targeted anticancer drugs, their clinical translation has remained limited to date (Table 1). Overall, there are three main limitations in developing glucose metabolism enzyme-targeted therapies. Firstly, a key challenge in developing small-molecule inhibitors is that most of the key enzymes of glucose metabolism exist in multiple isoforms, and the structures of the different isoforms are highly similar. The low selectivity of targeted drugs leads to the occurrence of adverse effects. In addition, targeted drugs may cause compensatory activation of other isoforms in the tumor, thus reducing the efficacy of the agents. Although several small-molecule targeted drugs have been demonstrated effective or even entered clinical trials [298], the poor targeting will produce toxic side effects, making it difficult to meet cancer treatment requirements [116–118]. Therefore, the development of highly selective inhibitors targeting glucose metabolism enzymes remains a challenging endeavor. To date, most gene sequences and protein structures of glucose metabolism enzymes have been annotated. Therefore, it is possible to design small-molecule inhibitors based on the crystal structure of glucose metabolism enzymes using computer-assisted drug design. The analysis of the binding sites in the crystal structure of glucose metabolism enzymes and their interactions with substrates, the clarification of the relevant properties of the binding sites, and the identification of key binding residues and possible binding regions will facilitate the research of structure-based small-molecule drug design or structure modification. We hope that researchers will combine crystal structure docking studies for targeted small-molecule drug design of glucose metabolism enzymes. Additionally, chemical structure optimization guided by pharmacophore modeling and traditional medicinal chemistry design ideas will eventually lead to the construction of a new class of active small-molecule compounds for cancer treatment.

Hypoxia is a prominent feature of the TME, but there is significant heterogeneity in metabolic patterns across different cancer cells. Cancer cells close to blood vessels are mainly metabolized by OXPHOS. It has been found that cancer cells close to blood vessels can take up lactate via MCT1 and use it for tricarboxylic acid cycle energy supply [309]. In contrast, cancer cells distant from blood vessels take up glucose for glycolytic energy supply and release lactate. Such cancer cells with different metabolic patterns exhibit a phenomenon known as metabolic symbiosis, which makes cancer cells more adaptable to the harsh TME [23]. Therefore, a single glycolytic targeting drug cannot destroy cancer cells with metabolic heterogeneity. Instead, the metabolic stress induced by targeted drugs may promote the metabolic reprogramming of cancer cells, such as a greater reliance on glutamine metabolism, thus causing drug resistance. One potentially effective strategy is...
to treat the metabolic patterns of different cellular subpopulations in the TME to render them relatively homogeneous and then target this relatively homogeneous metabolic population to achieve disruption. For example, antiangiogenic drugs are given before glucose metabolism enzyme-targeted drugs to make the cancer more dependent on glycolysis and thus achieve better therapeutic results. Chaturvedi B et al. [310] treated melanoma by inhibiting the mitochondrial respiration of cells with metformin, making the cells dependent on glycolysis before using LDH inhibitors and achieving better therapeutic results.

Table 1. Main targets and drugs of glucose metabolism of cancer cells.

| Enzyme | Target | Agents | Tumor Type | Study Phase |
|--------|--------|--------|------------|-------------|
| GLUT1  | GLUT1, GLUT2 | STF-31, WZB115, WZB117 | RCC, BC, LC | Preclinical |
| GLUT4  | Fasentin | WZB115 | PC, Lymphoma | Preclinical |
| GLUT5  | PH2007 | WZB117 | PC, Lymphoma | Preclinical |
| HK1/2  | Lonidamine | GLUT1/2 | HCC, BC, PC, LC, Melanoma, OC, etc. | Preclinical |
| HK1/2  | Lonidamine | GLUT3 | PC | Preclinical |
| HK2    | HK1/2 | Lonidamine | GLUT4 | Preclinical |
| HK2    | Lonidamine | GLUT5 | PC | Preclinical |
| HK2    | Lonidamine | 3-BrPA | HCC, BC, Pancreatic cancer, etc. | Phase I/II clinical trial |
| HK2    | Lonidamine | 3-PO | HCC, BC, Pancreatic cancer, etc. | Phase I/II clinical trial |
| PFK    | PFKB3 | PFK15 | RCC, HCC, CC, Gastric Cancer, etc. | Phase I clinical trial |
| PFK    | PFKB3 | PFK158 | RCC, HCC, CC, Gastric Cancer, etc. | Phase I clinical trial |
| PKM2   | Shikonin | PFK15 | HCC, BC, Bladder cancer | Preclinical |
| PKM2   | Shikonin | PFK15 | HCC, OC, etc. | Preclinical |
| LDHA   | LDHA | AT-101 | Chronic lymphoblastic leukemia | Phase I/II clinical trial |
| LDHA   | LDHA | Polyphenol E | BC, Colon cancer | Phase I/II clinical trial |

Abbreviations: 2,5-AM, 2,5-anhydro-d-mannitol; 2-DG, 2-deoxy-d-glucose; 3-BrPA, 3-bromopyruvate; BC, breast cancer; CC, colorectal cancer; GLUT, glucose transferase; HCC, hepatocellular carcinoma; HK, hexokinase; LC, lung cancer; LDH, lactate dehydrogenase; OC, ovarian cancers; PC, Prostate cancer; PFK, phosphofructokinase; PK, pyruvate kinase; RCC, renal cell carcinoma.

Another challenge for glucose metabolism enzyme-targeted therapies is the immune system’s response to the drug. Several anticancer immune cells are dependent on glycolysis for their function. For example, cytotoxic T lymphocytes require an adequate supply of glucose to produce gamma interferon for their anticancer effects; NK cells’ activation depends on glycolysis, and restriction of glycolysis causes the depletion of NK cells; DCs depend on glycolysis for IL-12 production and promotion of T-cell proliferation; Th1 and Th17 cells require glycolysis for differentiation; and macrophage secretion of tumor necrosis factor (TNF) is glycolysis dependent. In addition, M1 polarization of macrophages also depends on glycolysis [311–313]. Overall, targeted inhibition of glucose metabolism enzymes can inhibit the growth of cancer cells but also suppress the anticancer immune response. The regulation pattern of cancer cell metabolism is significantly different from that of other cells, and if the differences in metabolic regulation in cancer cells and immune cells can be identified, targeted therapies addressing these differences have the potential to solve the above problems.

5. Conclusions

Numerous studies have demonstrated that tumorigenesis and metastasis development are closely related to the metabolic reprogramming of cancer cells. Small-molecule inhibitors acting on key enzymes of glucose metabolism can regulate cancer metabolic reprogramming to inhibit cancer cell growth. Studies on some glucose metabolism modulators, such as 3-BrPA, LN, and 2-DG, have been conducted for decades and have shown significant inhibition in various cancers. However, due to side effects, most drugs have failed to enter the clinic. Metformin, VK, and other drugs have been widely used in other fields, and their safety and efficacy are guaranteed. However, further research and clinical
trials of their use in anticancer therapy are needed. Other small-molecule inhibitors of key enzymes, such as oxalate and salicylate sulfonamides, are still in their infancy, yet they have shown great potential for cancer treatment. In addition, some natural products have been identified to inhibit cancer cell growth by regulating key aerobic glycolysis enzymes, providing new ideas and strategies for developing anticancer drugs targeting glycolytic enzymes. However, the specific mechanisms of effect and targets are still unclear and need further investigation. Overall, developing anticancer drugs targeting glucose metabolism enzymes remains a significant challenge.

Most cancer cells have abnormal glucose metabolism, and the Warburg effect brings a new perspective to cancer treatment strategies. In this review, we have outlined the regulatory mode of glycolysis in cancer cells and presented the regulatory mechanism of GLUT, HK, PFK, PK, LDH, and other transporters or metabolic enzymes as targets in cancers and developed target drugs. Due to the unique metabolic features of cancer cells, the development and clinical translation of targeted therapeutic agents should be strengthened. Targeted glucose metabolizing enzyme drugs have been shown to have efficient anticancer effects in a variety of tumor models. Although no single glucose metabolism modulator is currently used in first-line clinical cancer treatment, combining glucose metabolism modulators with conventional anticancer drugs may become a promising cancer treatment strategy. Therefore, subsequent studies can not only explore the prognostic effects of glycolytic enzyme inhibitors on cancer patients but also accelerate the exploration of the combined application of glucose metabolism enzyme inhibitors and other anticancer drugs and translate the results into clinical treatment. With the development of new technologies such as high-throughput multi-omics and spatial omics, the heterogeneity of cancer cells and immune cells will be further elucidated, and therapeutic drugs targeting the glucose metabolism of malignant tumors will become an essential complement to existing treatments, thus changing the current state of cancer therapy.

**Author Contributions:** Conceptualization, C.H., L.W. and B.Z.; writing—original draft preparation, Y.Z.; writing—review and editing, Q.L., Z.H., B.L. and E.C.N.; supervision, C.H., L.W. and B.Z.; funding acquisition, B.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Clinical Research Incubation Project, West China Hospital, Sichuan University (Grant No. 2021HXFH022); the Science and Technology Department of Sichuan Province (Grant No. 22GJHZ0015); the Beijing Medical Award Foundation (Grant No. YXJL-2021-1009-0660); the 1·3·5 project for disciplines of excellence (ZYGD22007); and the National Natural Science Foundation of China (82130082).

**Acknowledgments:** The authors acknowledge BioRender (www.biorender.com, accessed on 22 August 2022), which was used to create the figures in this review.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. *Annu. Rev. Cell Dev. Biol.* **2011**, *27*, 441–464. [CrossRef] [PubMed]
2. Pavlova, N.N.; Thompson, C.B. The emerging hallmarks of cancer metabolism. *Cell Metab.* **2016**, *23*, 27–47. [CrossRef] [PubMed]
3. Ben-Haim, S.; Ell, P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. *J. Nucl. Med.* **2009**, *50*, 88–99. [CrossRef] [PubMed]
4. Bravata, V.; Stefano, A.; Cammarata, F.P.; Minafra, L.; Russo, G.; Nicolosi, S.; Pulizzi, S.; Gelfi, C.; Gilardi, M.C.; Messa, C. Genotyping analysis and 18FDG uptake in breast cancer patients: A preliminary research. *J. Exp. Clin. Cancer Res.* **2013**, *32*, 23. [CrossRef]
5. Bomanji, J.B.; Costa, D.C.; Ell, P.J. Clinical role of positron emission tomography in oncology. *Lancet Oncol.* **2001**, *2*, 157–164. [CrossRef]
6. Flavahan, W.A.; Wu, Q.; Hitomi, M.; Rahim, N.; Kim, Y.; Sloan, A.E.; Weil, R.J.; Nakano, I.; Sarkaria, J.N.; Stringer, B.W.; et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. *Nat. Neurosci.* **2013**, *16*, 1373–1382. [CrossRef] [PubMed]
7. Cao, M.; Isaac, R.; Yan, W.; Ruan, X.; Jiang, L.; Wan, Y.; Wang, J.; Wang, E.; Caron, C.; Neben, S.; et al. Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. *Nat. Cell Biol.* **2022**, *24*, 954–967. [CrossRef] [PubMed]

8. Szablewski, L. Expression of glucose transporters in cancers. *Biochim. Biophys. Acta* **2013**, *1835*, 164–169. [CrossRef]

9. Seyfried, T.N.; Marsh, J.; Shelton, L.M.; Huyserentruyt, L.C.; Mukherjee, P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? *Epilepsy Res.* **2012**, *100*, 310–326. [CrossRef]

10. Luo, Y.; Li, Y.; Huang, Z.; Li, X.; Wang, Y.; Hou, J.; Zhou, S. A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy. *Nano Lett.* **2022**, *22*, 6418–6427. [CrossRef]

11. Yu, J.; Wei, Z.; Li, Q.; Wan, F.; Chao, Z.; Zhang, X.; Lin, L.; Meng, H.; Tian, L. Advanced Cancer Starvation Therapy by Simultaneous Deprivation of Lactate and Glucose Using a MOF Nanoplatform. *Adv. Sci.* **2021**, *8*, e2014647. [CrossRef]

12. Zhang, J.; Liang, C.; Wei, Z.; Yang, W.; Ge, W.; Qu, X.; Si, W.; Wang, W.; Mou, X.; Dong, X. TME-triggered MnSiO3@Met@GOx nanosystem for ATP dual-inhibited starvation/chemodynamic synergistic therapy. *Biomaterials* **2022**, *287*, 121682. [CrossRef]

13. Champ, C.E.; Palmer, J.D.; Volek, J.S.; Werner-Wasik, M.; Andrews, D.W.; Evans, J.J.; Glass, J.; Kim, L.; Shi, W. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *J. Neurooncol.* **2014**, *117*, 125–131. [CrossRef] [PubMed]

14. Sainero-Alcolado, L.; Liano-Pons, J.; Ruiz-Perez, M.V.; Arsenian-Henriksson, M. Targeting mitochondrial metabolism for precision medicine in cancer. *Cell Death Differ.* **2022**, *29*, 1304–1317. [CrossRef] [PubMed]

15. Volland, J.M.; Kaupp, J.; Schmitz, W.; Wunsch, A.C.; Balint, J.; Mollmann, M.; El-Mesery, M.; Frackmann, K.; Peter, L.; Hartmann, S.; et al. Mass Spectrometric Metabolic Fingerprinting of 2-Deoxy-D-Glucose (2-DG)-Induced Inhibition of Glycolysis and Comparative Analysis of Methionine Restriction versus Glucose Restriction under Perfusion Culture in the Murine L929 Model System. *Int. J. Mol. Sci.* **2022**, *23*, 9220. [CrossRef] [PubMed]

16. Libertti, M.V.; Locasale, J.W. The Warburg effect: How does it benefit cancer cells? *Trends Biochem. Sci.* **2016**, *41*, 211–218. [CrossRef] [PubMed]

17. Ducker, G.S.; Rabinowitz, J.D. One-carbon metabolism in health and disease. *Cell Metab.* **2017**, *25*, 27–42. [CrossRef]

18. Husain, Z.; Huang, Y.; Seth, P.; Sukhatme, V.P. Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. *J. Immunol.* **2019**, *196*, 1491–1495. [CrossRef]

19. Angelin, A.; Gil-de-Gomez, L.; Dahtia, S.; Jiao, J.; Guo, L.; Levine, M.H.; Wang, Z.; Quinn, W.J.; III; Kopinski, P.K.; Wang, L. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. *Cell Metab.* **2017**, *25*, 1282–1293. [CrossRef]

20. Zhang, D.; Tang, Z.; Huang; H.; Zhou, G.; Cui, C.; Weng, Y.; Liu, W.; Kim, S.; Lee, S.; Perez-Neut, M. Metabolic regulation of gene expression by histone lactylation. *Nature 2019*, *574*, 575–580. [CrossRef]

21. Ishida, T.; Kobayashi, Y.; Ono, T.; Saito, S.; Kakehi, K.; Takahashi, Y.; Isobe, M.; Nishida, K.; Takigawa, M.; et al. Inhibitory effect of tumor cell–derived lactic acid on human T cells. *Blood* **2007**, *109*, 3812–3819. [CrossRef]

22. Ivashkiv, L.B. The hypoxia–lactate axis tempers inflammation. *Nat. Rev. Immunol.* **2020**, *20*, 85–86. [CrossRef]

23. Ippolito, L.; Morandi, A.; Giannoni, E.; Chiarugi, P. Lactate: A metabolic driver in the tumor landscape. *Trends Biochem. Sci.* **2019**, *44*, 153–166. [CrossRef]

24. Faubert, B.; Solmonson, A.; DeBeardinis, R.J. Metabolic reprogramming and cancer progression. *Science 2020*, *368*, eaaw5473. [CrossRef]

25. Ohshima, K.; Morii, E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. *Metabolites 2021*, *11*, 28. [CrossRef]

26. Yoshida, G.J. Metabolic reprogramming: The emerging concept and associated therapeutic strategies. *J. Exp. Clin. Cancer Res.* **2015**, *34*, 1–10. [CrossRef]

27. Stein, E.M.; DiNardo, C.D.; Fathi, A.T.; Mims, A.S.; Pratz, K.W.; Savona, M.R.; Stein, A.S.; Stone, R.M.; Winer, E.S.; Seet, C.S.; et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study. *Blood 2021*, *137*, 1792–1803. [CrossRef]

28. Chang, S.M.; Vander Heiden, M.G. Inhibiting GLUTony in cancer. *Cell Chem. Biol.* **2022**, *29*, 353–355. [CrossRef]

29. Thorens, B.; Mueckler, M. Glucose transporters in the 21st Century. *Am. J. Physiol.-Endocrinol. Metab.* **2010**, *298*, E141–E145. [CrossRef]

30. Mueckler, M.; Thorens, B. The SLC2 (GLUT) family of membrane transporters. *Mol. Asp. Med.* **2022**, *29*, 121–138. [CrossRef]

31. Bao, Y.; Zhong, J.T.; Shen, L.F.; Dai, L.B.; Zhou, S.H.; Fan, J.; Yao, H.T.; Lu, Z. Effect of Glut-1 and HIF-1alpha double knockout on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway. *J. Cell Mol. Med.* **2022**, *26*, 2881–2894. [CrossRef]

32. Sharma, V.; Singh, T.G.; Mannan, A. Therapeutic implications of glucose transporters (GLUT) in cerebral ischemia. *Neurochem Res.* **2022**, *47*, 2173–2186. [CrossRef] [PubMed]

33. Barron, C.C.; Bilan, P.J.; Tsakiris, T.; Tsiani, E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. *Metabolism 2016*, *65*, 124–139. [CrossRef] [PubMed]

34. Bukkuri, A.; Gatenby, R.A.; Brown, J.S. GLUT1 production in cancer cells: A tragedy of the commons. *NPJ Syst. Biol. Appl.* **2022**, *8*, 22. [CrossRef]

35. Guo, Z.; Cheng, Z.; Wang, J.; Liu, W.; Peng, H.; Wang, Y.; Rao, A.S.; Li, R.J.; Ying, X.; Korangath, P. Discovery of a potent GLUT inhibitor from a library of rapafucins by using 3D microarrays. *Angew. Chem. 2019*, *131*, 17318–17322. [CrossRef]
36. Granchi, C.; Tuccinardi, T.; Minutolo, F. Design, synthesis, and evaluation of GLUT1 inhibitors. Glucose Transp. 2018, 1713, 93–108.
37. Siebeneicher, H.; Bauser, M.; Buchmann, B.; Heisler, I.; Mueller, T.; Neuhau, R.; Rehwinkel, H.; Telser, J.; Zorn, L. Identification of novel GLUT inhibitors. Bioorg. Med. Chem. Lett. 2016, 26, 1732–1737. [CrossRef]
38. Wei, C.; Bai, R.; Sharma, H.; Heitmeier, M.; Jain, A.D.; Matulis, S.M.; Nooka, A.K.; Mishra, R.K.; Hruz, P.W.; Schultz, G.E. Development of GLUT4-selective antagonists for multiple myeloma therapy. Eur. J. Med. Chem. 2017, 139, 573–586. [CrossRef]
39. Chen, W.-L.; Wang, Y.-Y.; Zhao, A.; Xie, L.; Xie, G.; Su, M.; Zhao, L.; Liu, J.; Qu, C.; Wei, R. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell 2016, 30, 779–791. [CrossRef]
40. González, P.S.; O’Prey, J.; Cardaci, S.; Barthet, V.J.; Sakamaki, J.-i.; Beaumatin, F.; Roseweir, A.; Gay, D.M.; Mackay, G.; Malviya, G. Mannose impairs tumor growth and enhances chemotherapy. Nature 2018, 563, 719–723. [CrossRef]
41. Robichaud, T.; Appleyard, A.N.; Herbert, R.B.; Henderson, P.J.; Carruthers, A. Determinants of ligand binding affinity and cooperativity at the GLUT1 endofacial site. Biochemistry 2011, 50, 3137–3148. [CrossRef]
42. Chan, D.A.; Sutphin, P.D.; Nguyen, P.; Turcotte, S.; Lai, E.W.; Banh, A.; Reynolds, G.E.; Chen, L.; Schlessinger, A. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 2011, 3, 94ra70. [CrossRef]
43. Kraus, D.; Reckenbeil, J.; Veit, N.; Kuerbig, M.; Meisenheimer, M.; Beier, I.; Stark, H.; Winter, J.; Probstmeier, R. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: A re-evaluation. Cell Oncol. 2018, 41, 485–494. [CrossRef]
44. Pliszka, M.; Szablewski, L. Glucose Transporters as a Target for Anticancer Therapy. Cancers 2021, 13, 4184. [CrossRef]
45. Zhao, Y.; Butler, E.B.; Tan, M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013, 4, e532. [CrossRef]
46. Liu, Y.; Cao, Y.; Zhang, W.; Bergmeier, S.; Qian, Y.; Akbar, H.; Colvin, R.; Ding, J.; Tong, L.; Wu, S. A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo. A Glut1 Inhibitor Reduces Cancer Growth In Vitro and In Vivo. Mol. Cancer Ther. 2012, 11, 1672–1682. [CrossRef]
47. Ojelabi, O.A.; Lloyd, K.P.; Simon, A.H.; De Zutter, J.K.; Carruthers, A. WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxybenzoate) inhibits GLUT1-mediated sugar transport by binding reversibly at the exofacial sugar binding site. J. Biol. Chem. 2016, 291, 26762–26772. [CrossRef]
48. Yakisich, J.S.; Azad, N.; Kaushik, V.; Iyer, A.K.V. The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells. Stem Cells Int. 2016, 2016, 1908–1916. [CrossRef] [PubMed]
49. Siebeneicher, H.; Cleve, A.; Rehwinkel, H.; Neuhau, R.; Müller, T.; Bauser, M.; Buchmann, B. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 2016, 11, 2261–2271. [CrossRef]
50. Wu, Q.; Deblois, G.; Cruickshank, J.; Duan, S.; Lima-Fernandes, E.; Haight, J.; Tonekaboni, S.A.M.; Fortier, A.-M.; Kuasne, H.; McKe, T.D. GLUT1 inhibition blocks growth of Rb1-positive triple negative breast cancer. Nat. Commun. 2020, 11, 4205. [CrossRef]
51. Ma, Y.; Wang, W.; Idowu, M.O.; Oh, U.; Wang, X.-Y.; Temkin, S.M.; Fang, X. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: Anti-tumor activity of BAY-876. Cancers 2018, 11, 33. [CrossRef] [PubMed]
52. Li, W.; Qu, G.; Choi, S.-C.; Cornaby, C.; Titov, A.; Kanda, N.; Teng, X.; Wang, H.; Morel, L. Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters. Front. Immunol. 2019, 10, 833. [CrossRef] [PubMed]
53. Wu, K.-H.; Ho, C.-T.; Chen, Z.-F.; Chen, L.-C.; Whang-Peng, J.; Lin, T.-N.; Ho, Y.-S. The apple polyphenol phloretin inhibits breast cancer cell migration and proliferation via inhibition of signals by type 2 glucose transporter. J. Food Drug Anal. 2018, 26, 221–231. [CrossRef] [PubMed]
54. Ung, P.M.-U.; Song, W.; Cheng, L.; Zhao, X.; Hu, H.; Chen, L.; Schlessinger, A. Inhibitor discovery for the human GLUT1 from homology modeling and virtual screening. ACS Chem. Biol. 2016, 11, 1908–1916. [CrossRef] [PubMed]
55. Karageorgis, G.; Cebeñes, E.; Ceballos, J.; Schwalfenberg, M.; Sievers, S.; Ostermann, C.; Pahl, A.; Ziegler, S.; Waldmann, H. Chromopyrones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3. Nat. Chem. 2018, 10, 1103–1111. [CrossRef] [PubMed]
56. Tyagi, K.; Mandal, S.; Roy, A. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission. Biochim. Biophys. Acta Rev. Cancer 2021, 1876, 188563. [CrossRef] [PubMed]
57. Karageorgis, G.; Foley, D.J.; Laraia, L.; Waldmann, H. Principle and design of pseudo-natural products. Nat. Chem. 2020, 12, 227–235. [CrossRef]
58. Casiraghi, A.; Bensimon, A.; Superti-Furga, G. Recent developments in ligands and chemical probes targeting solute carrier transporters. Curr. Opin. Chem. Biol. 2016, 26, 52–63. [CrossRef]
59. Zhang, D.; Wang, Y.; Dong, L.; Huang, Y.; Yuan, J.; Ben, W.; Yang, Y.; Ning, N.; Lu, M.; Guan, Y. Therapeutic role of EF 24 targeting glucose transporter 1-mediated metabolism and metastasis in ovarian cancer cells. Cancer Sci. 2013, 104, 1690–1696. [CrossRef]
60. George Thompson, A.M.; Iancu, C.V.; Nguyen, T.T.H.; Kim, D.; Choe, J.-Y. Inhibition of human GLUT1 and GLUT5 by plant carbohydrate products; insights into transport specificity. Sci. Rep. 2015, 5, 12804. [CrossRef]
61. Tilekar, K.; Upadhyay, N.; Iancu, C.V.; Pokrovsky, V.; Choe, J.-Y.; Ramaa, C. Power of two: Combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer. Biochim. Biophys. Acta (BBA)-Rev. Cancer 2020, 1874, 188457. [CrossRef]
86. Correia-Branco, A.; Azevedo, C.F.; Araujo, J.R.; Guimaraes, J.T.; Faria, A.; Keating, E.; Martel, F. Xanthohumol impairs glucose uptake by a human first-trimester extravillous trophoblast cell line (HTR-8/SVneo cells) and impacts the process of placentation. *Mhr Basic. Reprod. Med.* 2015, 21, 803–815. [CrossRef]

87. Sage, J.M.; Cura, A.J.; Lloyd, K.P.; Carruthers, A. Caffeine inhibits glucose transport by binding at the GLUT1 nucleotide-binding site. *Am. J. Physiol.-Cell Physiol.* 2015, 308, C827–C834. [CrossRef]

88. Hyun, D.H. Insights into the New Cancer Therapy through Redox Homeostasis and Metabolic Shifts. *Cancers* 2020, 12, 1822. [CrossRef]

89. Shahruzaman, S.H.; Mustafa, M.F.; Ramli, S.; Maniam, S.; Fakurazi, S.; Maniam, S. The Cytotoxic Properties of *Baeckea frutescens* Branches Extracts in Eliminating Breast Cancer Cells. *Evid. Based Complement Altern. Med.* 2019, 2019, 9607950. [CrossRef]

90. Mathupala, S.P.; Rempel, A.; Pedersen, P.L. Glucose catabolism in cancer cells: Identification and characterization of a marked GLUT1 hexose transporter by methylxanthines reveals an exofacial regulatory binding site. *Am. J. Physiol.-Cell Physiol.* 2012, 303, C530–C539. [CrossRef]

91. Hevia, D.; González-Menéndez, P.; Quiros-González, I.; Miar, A.; Rodríguez-García, A.; Tan, D.X.; Reiter, R.J.; Mayo, J.C.; Sainz, R.M. Melatonin uptake through glucose transporters: A new target for melatonin inhibition of cancer. *J. Pineal Res.* 2015, 58, 234–250. [CrossRef]

92. Shahruzaman, S.H.; Mustafa, M.F.; Ramli, S.; Maniam, S.; Fakurazi, S.; Maniam, S. The Cytotoxic Properties of *Baeckea frutescens* Branches Extracts in Eliminating Breast Cancer Cells. *Evid. Based Complement Altern. Med.* 2019, 2019, 9607950. [CrossRef]

93. Cheng, X.; Yan, H.; Pang, S.; Ya, M.; Qu; F.; Qin, P.; Zeng, C.; Lu, Y. Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products. *Front. Chem.* 2022, 10, 963004. [CrossRef] [PubMed]

94. Feitosa, R.C.; Ishikawa, E.S.A.; Silva, M.; Silva-Junior, A.A.D.; Oliveira-Nascimento, L. Five decades of doxycycline: Does nanotechnology improve its properties? *Int. J. Pharm.* 2022, 618, 121655. [CrossRef]

95. Seker Karatoprak, G.; Kupeli Akkol, E.; Yucel, C.; Bahadir Acikara, O.; Sobarzo-Sanchez, E. Advances in Understanding the Role of Aloe Emoidin and Targeted cytotoxic Drug Delivery Systems in Cancer. *Oxid Med. Cell Longev.* 2022, 2022, 7928200. [CrossRef]

96. Choi, J.; Mathew, S.; Oerter, S.; Appelt-Menzel, A.; Hansmann, J.; Schmitz, T. Online Measurement System for Dynamic Flow Bioreactors to Study Barrier Integrity of hiPSC-Based Blood-Brain Barrier In Vitro Models. *Bioengineering* 2022, 9, 39. [CrossRef]

97. Figueiras, A.; Domingue, C.; Jacar, I.; Santos, A.I.; Parra, A.; Pais, A.; Alvarez-Lorenzo, C.; Concheiro, A.; Kabanov, A.; Cabral, H.; et al. New Advances in Biomedical Application of Polymeric Micelles. *Pharmaceutics* 2022, 14, 1700. [CrossRef]

98. Jannat, T.; Hossain, M.J.; El-Shehawi, A.M.; Kuddis, M.R.; Albugami, S.; Jafri, I.; El-Shazly, M.; Haque, M.R. Chemical and Pharmacological Profiling of *Wrightia coccinea* (Roxb. Ex Hornem.) Sims Focusing Antioxidant, Cytotoxic, Antidiarrheal, Hypoglycemic, and Analogic Properties. *Molecules* 2022, 27, 4024. [CrossRef] [PubMed]

99. Wilson, J.E. Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. *Cancer Cell* 2007, 305–316. [CrossRef]

100. Wolf, A.; Agnihotri, S.; Micallef, J.; Mukherjee, J.; Sabha, N.; Cairns, R.; Hawkins, C.; Guha, A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. *J. Exp. Biol.* 2003, 206, 2049–2057. [CrossRef]

101. Mathupala, S.P.; Heese, C.; Pedersen, P.L. Glyceraldehyde 3-phosphate dehydrogenase is a key enzyme in the Warburg effect and operates as a redox sensor in cancer cells. *Antioxid. Redox Signal.* 2015, 20, 157. [CrossRef]

102. Mathupala, S.P.; Heese, C.; Pedersen, P.L. Glyceraldehyde 3-phosphate dehydrogenase is a key enzyme in the Warburg effect and operates as a redox sensor in cancer cells. *Antioxid. Redox Signal.* 2015, 20, 157. [CrossRef]

103. Hu, J.; Cao, J.; Topatana, W.; Juengpanich, S.; Li, S.; Zhang, B.; Shen, J.; Cai, L.; Cai, X.; Chen, M. Targeting mutant p53 for cancer therapy: Direct and indirect strategies. *J. Hematol. Oncol.* 2021, 14, 157. [CrossRef]

104. Liu, S.; Yan, B.; Li, W.; Chen, L.; Xiao, D.; Xi, S.; Jiang, Y.; Dong, X.; An, J.; Chen, X.; et al. As a novel p53 direct target, bidirectional activation response of the type II hexokinase gene to hypoxic conditions. *J. Biol. Chem.* 2001, 272, 22776–22780. [CrossRef]

105. Kaghad, M.; Bonnet, H.; Yang, A.; Creancier, L.; Biscan, J.C.; Valent, A.; Minty, A.; Chalon, P.; Leleis, J.M.; Dumont, X.; et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* 1997, 90, 809–819. [CrossRef]

106. Yang, A.; Kaghad, M.; Wang, Y.; Gillett, E.; Fleming, M.D.; Dotsch, V.; Andrews, N.C.; Caput, D.; McKeon, F. p63 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol. Cell* 1998, 2, 305–316. [CrossRef]

107. Venkatakrishnan, A.; Raulji, P.; Norton, W.; Chakravarti, D.; Coarfa, C.; Su, X.; Sandur, S.K.; Ramirez, M.S.; Lee, J.; Kingsley, C.V.; et al. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. *Nature 2015*, 517, 626–630. [CrossRef]

108. Viticchie, G.; Agostini, M.; Lena, A.M.; Mancini, M.; Zhou, H.; Zolla, L.; Dinsdale, D.; Saintigny, G.; Melino, G.; Candi, E. p63 supports aerobic respiration through hexokinase II. *Proc. Natl. Acad. Sci. USA* 2015, 112, 11577–11582. [CrossRef]

109. Patra, K.C.; Wang, Q.; Bhaskar, P.T.; Miller, L.; Wang, Z.; Wheaton, W.; Chandel, N.; Laakso, M.; Muller, W.J.; Allen, E.L. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. *Cancer Cell* 2013, 24, 213–228. [CrossRef]
110. DeWaal, D.; Nogueira, V.; Terry, A.R.; Patra, K.C.; Jeon, S.-M.; Guzman, G.; Au, J.; Long, C.P.; Antoniewicz, M.R.; Hay, N. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. *Nat. Commun.* 2018, 9, 446. [CrossRef]

111. Neary, C.L.; Pasternino, J.G. Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells. *J. Cell. Physiol.* 2013, 228, 1943–1948. [CrossRef]

112. García, S.N.; Guedes, R.C.; Marques, M.M. Unlocking the potential of HK2 in cancer metabolism and therapeutics. *Curr. Med. Chem.* 2019, 26, 7285–7322. [CrossRef]

113. Nawaz, M.H.; Ferreira, J.C.; Nedyalkova, L.; Zhu, H.; Carrasco-Lopez, C.; Kirmizialtin, S.; Rabeh, W.M. The catalytic inactivation of the N-half of human hexokinase 2 and structural and biochemical characterization of its mitochondrial conformation. *Biosci. Rep.* 2018, 38, 38. [CrossRef] [PubMed]

114. Shan, W.; Zhou, Y.; Tam, K.Y. The development of small-molecule inhibitors targeting hexokinase 2. *Drug Discov. Today* 2022, 27, 2574–2585. [CrossRef] [PubMed]

115. Wang, L.; Yang, Q.; Peng, S.; Liu, X. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persistier cancer cells. *OncoTargets Ther.* 2019, 12, 5359. [CrossRef] [PubMed]

116. Mulley, P.; Olinger, A.; Tummalra, H. 2-Deoxyglucose induces cell cycle arrest and apoptosis in colorectal cancer cells independent of its glycolysis inhibition. *Nutr. Cancer* 2015, 67, 514–522. [CrossRef] [PubMed]

117. Fulda, S.; Galluzzi, L.; Kroemer, G. Targeting mitochondria for cancer therapy. *Nat. Rev. Drug Discov.* 2010, 9, 447–464. [CrossRef] [PubMed]

118. Coleman, M.C.; Asbury, C.R.; Daniels, D.; Du, J.; Aykin-Burns, N.; Smith, B.J.; Li, L.; Spitz, D.R.; Cullen, J.J. 2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. *Free. Radic. Biol. Med.* 2008, 44, 322–331. [CrossRef]

119. Simons, A.L.; Ahmad, I.M.; Mattson, D.M.; Dornfeld, K.J.; Spitz, D.R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. *Cancer Res.* 2007, 67, 3364–3370. [CrossRef]

120. Maschek, G.; Savaraj, N.; Priebe, W.; Braunischweiger, P.; Hamilton, K.; Tidmarsh, G.F.; De Young, L.R.; Lampidis, T.J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. *Cancer Res.* 2004, 64, 31–34. [CrossRef]

121. Pajak, B.; Siwick, E.; Sołyka, M.; Priebe, A.; Zieliński, R.; Fokt, I.; Ziemniak, M.; Jaskiewicz, A.; Borowski, R.; Domoradzki, T. 2-Deoxy-d-glucose and its analogs: From diagnostic to therapeutic agents. *Int. J. Mol. Sci.* 2019, 21, 234. [CrossRef]

122. Li, L.; Fath, M.A.; Scarbrough, P.M.; Watson, W.H.; Spitz, D.R. Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer. *Redox Biol.* 2015, 4, 127–135. [CrossRef]

123. Raez, L.E.; Papadopoulos, K.; Ricart, A.D.; Chiorean, E.G.; DiPaola, R.S.; Stein, M.N.; Rocha Lima, C.M.; Schlesselman, J.J.; Tolba, K.; Langmuir, V.K. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. *Cancer Chemother. Pharmacol.* 2013, 71, 523–530. [CrossRef]

124. Belzacq, A.-S.; El Hamel, C.; Vieira, H.L.; Cohen, I.; Haouzi, D.; Métrier, D.; Marchetti, P.; Brenner, C.; Kroemer, G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. *Oncogene* 2001, 20, 7579–7587. [CrossRef]

125. Nath, K.; Guo, L.; Nancolas, B.; Nelson, D.S.; Shestov, A.A.; Lee, S.-C.; Roman, J.; Zhou, R.; Leeper, D.B.; Halestrap, A.P. Mechanism of antineoplastic activity of lonidamine. *Biochim. Biophys. Acta (BBA)-Rev. Cancer* 2015, 1857, 514–522. [CrossRef] [PubMed]

126. Gadducci, A.; Brunetti, I.; Mutini, M.; Fanucchi, A.; Dargenio, F.; Giannessi, P.; Conte, P. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. *Eur. J. Cancer* 1994, 30, 1432–1435. [CrossRef]

127. De Lena, M.; Lorusso, V.; Bottalico, C.; Brandi, M.; De Mitrio, A.; Catino, A.; Guida, M.; Latorre, A.; Leone, B.; Vallejo, C. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. *J. Clin. Oncol.* 1997, 15, 3208–3213. [CrossRef]

128. De Marinis, F.; Rinaldi, M.; Ardizzoni, A.; Bruzzi, P.; Pennucci, M.C.; Portalone, L.; D’Aprile, M.; Ripanti, P.; Romano, F.; Belli, M. The role of vimentine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: A phase III randomized fonicap trial. *Tumori* J. 1999, 85, 177–182. [CrossRef]

129. Berruti, A.; Bitossi, R.; Gorzegno, G.; Bottini, A.; Alquati, P.; De Matteis, A.; Nuzzo, F.; Giardina, G.; Danese, S.; De Lena, M. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design. *J. Clin. Oncol.* 2002, 20, 4150–4159. [CrossRef]

130. Price, G.S.; Page, R.L.; Riviere, J.E.; Cline, J.M.; Thrall, D. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. *Cancer Chemother. Pharmacol.* 1996, 38, 129–135. [CrossRef]

131. Nath, K.; Nelson, D.S.; Heitjan, D.F.; Leeper, D.B.; Zhou, R.; Glickson, J.D. Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. *NMR Biomed.* 2015, 28, 281–290. [CrossRef]
158. Gao, X.; Han, H. Jolkioside B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells. J. Cell. Biochem. 2018, 119, 4967–4974. [CrossRef]

159. Zhou, Y.; Zheng, X.; Lu, J.; Chen, W.; Li, X.; Zhao, L. Ginsenoside 20 (S)-Rg3 inhibits the warburg effect via modulating DNMT3A/MIR-332-3p/HK2 pathway in ovarian cancer cells. Cell. Physiol. Biochem. 2018, 45, 2548–2559. [CrossRef]

160. Agnihotri, S.; Mansouri, S.; Marsoufi, S.; Burrell, K.; Li, M.; Mamatjan, Y.; Liu, J.; Nejad, R.; Kumar, S.; Jalali, S.; Singh, S. K. Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Azoles Inhibit HK2 and GBM Growth. Clin. Cancer Res. 2019, 25, 844–855. [CrossRef]

161. Li, W.; Hao, J.; Zhang, L.; Cheng, Z.; Deng, X.; Shu, G. Astragalin reduces hexokinase 2 through increasing miR-125b to inhibit the proliferation of hepatocellular carcinoma cells in vitro and in vivo. J. Agric. Food Chem. 2017, 65, 5961–5972. [CrossRef] [PubMed]

162. Chesney, J. 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase and tumor cell glycolysis. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9, 535–539. [CrossRef]

163. Houddane, A.; Bultot, L.; Novellasdemunt, L.; Johanns, M.; Gueuning, M.-A.; Vertommen, D.; Coutie, P.G.; Bartrons, R.; Hue, L.; Rider, M.H. Role of Akt/PKB and PFKFB4 isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes. Cell. Signal. 2017, 34, 23–37. [CrossRef] [PubMed]

164. Lu, L.; Chen, Y.; Zhu, Y. The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget 2017, 8, 62793. [CrossRef] [PubMed]

165. Brooke, D.G.; van Dam, E.M.; Watts, C.K.; Khoury, A.; Dziadek, M.A.; Brooks, H.; Graham, L.-J.K.; Flanagan, J.U.; Denny, W.A. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2, 6-bisphosphatase 3 (PFKFB3). Bioorg. Med. Chem. 2014, 22, 1029–1039. [CrossRef] [PubMed]

166. Yalcin, A.; Telang, S.; Clem, B.; Chesney, J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatas in cancer. Exp. Mol. Pathol. 2009, 86, 174–179. [CrossRef] [PubMed]

167. Bartrons, R.; Rodriguez-Garcia, A.; Simon-Molas, H.; Castano, E.; Manzano, A.; Navarro-Sabaté, À. The potential utility of PFKFB3 as a therapeutic target. Expert Opin. Ther. Targets 2018, 22, 659–674. [CrossRef] [PubMed]

168. Han, J.; Meng, Q.; Xi, Q.; Wang, H.; Wu, G. PFKFB3 was overexpressed in gastric cancer patients and promoted the proliferation and migration of gastric cancer cells. Cancer Biomark. 2017, 18, 249–256. [CrossRef]

169. Li, J.; Zhang, S.; Liao, D.; Zhang, Q.; Chen, C.; Yang, X.; Jiang, D.; Pang, J. Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma. BMC Cancer 2022, 22, 83. [CrossRef]

170. Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M.A.; Arumugam, S.; Dean, W.L.; Eaton, J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 2008, 7, 110–120. [CrossRef]

171. Clem, B.F.; O’Neal, J.; Tapolsky, G.; Clem, A.L.; Imbert-Fernandez, Y.; Kerr, D.A.; Klarer, A.C.; Redman, R.; Miller, D.M.; Trent, J.O. Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. Targeting PFKFB3 in Cancer. Cancers 2016, 9, 4568. [CrossRef] 26 of 32

172. Shi, L.; Pan, H.; Liu, Z.; Xie, J.; Han, W. Roles of PFKFB3 in cancer. Signal Transduct. Target. Ther. 2017, 2, 17044. [CrossRef]

173. Mondal, S.; Roy, D.; Sarkar Bhattacharya, S.; Jin, L.; Jung, D.; Zhang, S.; Kologera, E.; Staub, J.; Wang, Y.; Xuyang, W. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitization in gynecologic cancers. Int. J. Cancer 2019, 144, 178–189. [CrossRef]

174. Seo, M.; Kim, J.-D.; Neau, D.; Sehgal, I.; Lee, Y.-H. Structure-based development of small molecule PFKFB3 inhibitors: A framework for potential novel cancer therapeutic targeting the Warburg effect. PLoS ONE 2011, 6, e24179. [CrossRef]

175. Li, F.-I.; Liu, J.-P.; Bao, R.-X.; Yan, G.; Feng, X.; Xu, Y.-P.; Sun, Y.-P.; Yan, W.; Ling, Z.-Q.; Xiong, Y. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat. Commun. 2018, 9, 508. [CrossRef]

176. Feng, Y.; Wu, L. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival. Biochim. Biophys. Res. Commun. 2017, 483, 897–903. [CrossRef]

177. Yan, S.; Zhou, N.; Zhang, D.; Zhang, K.; Zheng, W.; Bao, Y.; Yang, W. PFKFB3 inhibition attenuates oxaliplatin-induced autophagy and enhances its cytotoxicity in colon cancer cells. Int. J. Mol. Sci. 2019, 20, 5415. [CrossRef]

178. Zhu, Y.; Lu, L.; Qiao, C.; Shan, Y.; Li, H.; Qian, S.; Hong, M.; Zhao, H.; Li, J.; Yang, Z. Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor. Oncogene 2018, 37, 2837–2849. [CrossRef]

179. Telang, S.; Yaddanadupi, K.; Tapolsky, G.; Redman, R.; Chesney, J. Taking the sweet out of Th17 cells to potentiate immunoncology drugs. Cancer Res. 2016, 76, 557. [CrossRef]

180. Gustafsson, N.; Färnegårdh, K.; Bonagas, N.; Ninou, A.H.; Groth, P.; Wiita, E.; Jönsson, M.; Hallberg, K.; Lehto, J.; Pennisi, R. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat. Commun. 2018, 9, 3873. [CrossRef]

181. Lea, M.A.; Guzman, Y.; Desbordes, C. Inhibition of growth by combined treatment with inhibitors of lactate dehydrogenase and either phenformin or inhibitors of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3. Anticancer Res. 2016, 36, 1479–1488. [PubMed]

182. Wang, Y.; Qu, C.; Liu, T.; Wang, C. PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships. Eur. J. Med. Chem. 2020, 203, 112612. [CrossRef]

183. Kotowski, K.; Rosik, J.; Machaj, F.; Supplitt, S.; Wiczew, D.; Jabłońska, K.; Wiechec, E.; Ghavami, S.; Dziegieł, P. Role of PFKFB3 and PFKFB4 in cancer: Genetic basis, impact on disease development/progression, and potential as therapeutic targets. Cancers 2021, 13, 909. [CrossRef] [PubMed]
184. Li, Y.-H.; Li, X.-F.; Liu, J.-T.; Wang, H.; Fan, L.-L.; Li, J.; Sun, G.-P. PKM2, a potential target for regulating cancer. *Gene* 2018, 668, 48–53. [CrossRef] [PubMed]

185. McDonnell, S.R.; Hwang, S.R.; Rolland, D.; Muruga-Zamalloa, C.; Basrur, V.; Conlon, K.P.; Fermin, D.; Wolfe, T.; Raskind, A.; Ruan, C. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. *Blood J. Am. Soc. Hematol.* 2013, 122, 958–968. [CrossRef]

186. Yang, X.; Qian, K. Protein O-GlcNAcylation: Emerging mechanisms and functions. *Nat. Rev. Mol. Cell Biol.* 2017, 18, 452–465. [CrossRef]

187. Li, J.; Li, S.; Guo, J.; Li, Q.; Long, J.; Ma, C.; Ding, Y.; Yan, C.; Li, L.; Wu, Z. Natural product micheliolide (MCL) irreversibly activates pyruvate kinase M2 and suppresses leukemia. *J. Med. Chem.* 2018, 61, 4155–4164. [CrossRef]

188. Qi, H.; Ning, X.; Yu, C.; Ji, X.; Jin, Y.; McNutt, M.A.; Yin, Y. Succinylation-dependent mitochondrial translocation of PKM2 promotes cell survival in response to nutritional stress. *Cell Death Dis.* 2019, 10, 170. [CrossRef]

189. Liu, F.; Ma, F.; Wang, Y.; Hao, L.; Zeng, H.; Jia, C.; Wang, Y.; Liu, P.; Ong, I.M.; Li, B. PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis. *Nat. Cell Biol.* 2017, 19, 1358–1370. [CrossRef]

190. Martin, S.P.; Fako, V.; Dang, H.; Dominguez, D.A.; Khatib, S.; Ma, L.; Wang, H.; Zheng, W.; Wang, X.W. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. *J. Exp. Clin. Cancer Res.* 2020, 39, 99. [CrossRef]

191. Wang, Y.; Hao, F.; Nan, Y.; Qu, L.; Na, W.; Jia, C.; Chen, X. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis. *Int. J. Biol. Sci.* 2018, 14, 1883. [CrossRef]

192. Anastasiou, D.; Poulogiannis, G.; Asara, J.M.; Boxer, M.B.; Jiang, J.-k.; Shen, M.; Bellinger, G.; Sasaki, A.T.; Locasale, J.W.; Auld, D.S. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. *Science* 2011, 334, 1278–1283. [CrossRef]

193. Goldberg, M.S.; Sharp, P.A. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. *J. Exp. Med.* 2012, 209, 217–224. [CrossRef]

194. Chen, J.; Xie, J.; Jiang, Z.; Wang, B.; Wang, Y.; Hu, X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. *Oncogene* 2011, 30, 4297–4306. [CrossRef]

195. Tao, T.; Su, Q.; Xu, S.; Deng, J.; Zhou, S.; Zhuang, Y.; Huang, Y.; He, C.; He, S.; Peng, M. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. *J. Cell. Physiol.* 2019, 234, 3088–3104. [CrossRef]

196. Tang, J.-C.; Zhao, J.; Long, F.; Chen, J.-y.; Mu, B.; Jiang, Z.; Ren, Y.; Yang, J. Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo. *J. Cancer* 2018, 9, 32. [CrossRef]

197. Boulos, J.C.; Rahama, M.; Hegazy, M.-E.F.; Effertth, T. Shikonin derivatives for cancer prevention and therapy. *Cancer Lett.* 2019, 459, 248–267. [CrossRef]

198. Li, H.; Tong, Y.; Bai, L.; Ye, L.; Zhong, L.; Duan, X.; Zhu, Y. Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma. *Int. J. Biol. Macromol.* 2018, 107, 204–211. [CrossRef]

199. Tian, H.; Zhang, T.; Qin, S.; Huang, Z.; Zhou, L.; Shi, J.; Nice, E.C.; Xie, N.; Huang, C.; Shen, Z. Enhancing the therapeutic efficacy of nanoparticles for cancer treatme nt nt using versat ile targeted strategies. *J. Hematol. Oncol.* 2022, 15, 132. [CrossRef]

200. Kontogiannopoulos, K.N.; Assimopoulou, A.N.; Hatziantonioi, S.; Karatasos, K.; Demetzos, C.; Papageorgiou, V.P. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology. *Int. J. Pharm.* 2012, 422, 381–389. [CrossRef]

201. Kontogiannopoulos, K.N.; Tsermentseli, S.K.; Assimopoulou, A.N.; Papageorgiou, V.P. Sterically stabilized liposomes as a potent carrier for shikonin. *J. Liposome Res.* 2014, 24, 230–240. [CrossRef]

202. Li, J.; Zhou, S.; Yu, J.; Cai, W.; Yang, Y.; Kuang, X.; Liu, H.; He, Z.; Wang, Y. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenic cell death for synergistic chemo-immunotherapy. *J. Control Release* 2021, 335, 306–319. [CrossRef]

203. Assimopoulou, A.N.; Papageorgiou, V.P. Preparation and release studies of alkannin-containing microcapsules. *J. Microencapsul.* 2004, 21, 161–173. [CrossRef]

204. Kontogiannopoulos, K.N.; Assimopoulou, A.N.; Tsivintzelis, I.; Panayiotou, C.; Papageorgiou, V.P. Electrospun fiber mats containing shikonin and derivatives with potential biomedical applications. *Int. J. Pharm.* 2011, 409, 216–228. [CrossRef] [PubMed]

205. Wang, H.; Zhu, Z.; Zhang, G.; Lin, F.; Liu, Y.; Zhang, Y.; Feng, J.; Chen, W.; Meng, Q.; Chen, L. ASI411 Aptamer/Hyaluronic Acid-Bifunctionalized Microemulsion Co-Loading Shikonin and Docetaxel for Enhanced Antiglioma Therapy. *J. Pharm. Sci.* 2019, 108, 3684–3694. [CrossRef] [PubMed]

206. Jing, Q.; Ruan, H.; Li, J.; Wang, Z.; Pei, L.; Hu, H.; He, Z.; Wu, T.; Ruan, S.; Guo, T.; et al. Keratinocyte membrane-mediated nanodelivery system with dissolving microneedles for targeted therapy of skin diseases. *Biomaterials* 2021, 278, 121142. [CrossRef] [PubMed]

207. Li, J.; Zhao, M.; Xu, Y.; Hu, X.; Dai, Y.; Wang, D. Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment. *Int. J. Pharm.* 2021, 597, 120310. [CrossRef]

208. Nindawat, S.; Agrawal, V. Fabrication of silver nanoparticles using *Arnebia hispidissima* (Lehm.) A. DC. root extract and unravelling their potential biomedical applications. *Artif. Cells Nanomed. Biotechnol.* 2019, 47, 166–180. [CrossRef]
209. Tian, H.; Zhang, M.; Jin, G.; Jiang, Y.; Luan, Y. Cu-MOF chemodynamic nanoplatform via modulating glutathione and H2O2 in tumor microenvironment for amplified cancer therapy. J. Colloid Interface Sci. 2021, 587, 358–366. [CrossRef]

210. Tian, H.; Zhou, L.; Wang, Y.; Niu, N.; Niu, L.; Huang, C.; Zhang, H. A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis. J. Control Release 2022, 348, 590–600. [CrossRef]

211. Su, Q.; Luo, S.; Tan, Q.; Deng, J.; Zhou, S.; Peng, M.; Tao, T.; Yang, X. The role of pyruvate kinase M2 in anticancer therapeutic treatments. Oncol. Lett. 2019, 18, 5663–5672. [CrossRef]

212. Shang, D.; Wu, J.; Guo, H.; Xu, Y.; Liu, L.; Li, J. Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2. Int. J. Oncol. 2005, 30, 1848–1856. [CrossRef]

213. Liu, M.; Zhang, Z.; Wang, H.; Chen, X.; Jin, C. Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. Int. J. Biol. Sci. 2019, 15, 617. [CrossRef]

214. Ivanova, D.; Zhelev, Z.; Getsov, P.; Nikolova, B.; Aoki, I.; Higashi, T.; Bakalova, R. Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biol. 2018, 16, 352–358. [CrossRef]

215. Wellington, K.W.; Hitlshawyo, V.; Kolesnikova, N.I.; Saha, S.T.; Kaur, M.; Motadi, L.R. Anticancer activities of vitamin K3 analogues. Invest. New Drugs 2020, 38, 378–391. [CrossRef]

216. Ning, X.; Qi, H.; Li, R.; Li, Y.; Jin, Y.; McNutt, M.A.; Liu, J.; Yin, Y. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur. J. Med. Chem. 2017, 138, 343–352. [CrossRef]

217. Zhou, Y.; Huang, Z.; Su, J.; Li, J.; Zhao, S.; Wu, L.; Zhang, J.; He, Y.; Zhang, G.; Tao, J. Benserazide is a novel inhibitor targeting pyruvate kinase M2. J. Control Release 2018, 2450–2460. [CrossRef]

218. Shankar Babu, M.; Mahanta, S.; Lakhter, A.J.; Hato, T.; Paul, S.; Naidu, S.R. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2. PLoS ONE 2013, 13, e0191419. [CrossRef]

219. Feng, J.; Wu, L.; Ji, J.; Chen, K.; Yu, Q.; Zhang, J.; Chen, J.; Mao, Y.; Wang, F.; Dai, W. PKM2 is the target of proanthocyanidin B2 inhibition. Front. Cell. Neurosci. 2019, 38, 204. [CrossRef]

220. Zhu, S.; Guo, Y.; Zhang, X.; Liu, H.; Yin, M.; Chen, X.; Peng, C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Front. Immunol. 2019, 10, 110405. [CrossRef] [PubMed]

221. Zhao, H.; Han, L.; Jiao, Y.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

222. Wang, H.; Han, L.; Jiao, Y.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

223. Zhao, H.; Han, L.; Jiao, Y.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

224. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

225. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

226. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

227. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

228. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

229. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

230. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

231. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

232. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

233. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

234. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]

235. Yang, R.; Fang, X.-L.; Zhen, Q.; Chen, Q.-Y.; Feng, C. Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN. Colloids Surf. B Biointerfaces 2019, 182, 110405. [CrossRef] [PubMed]
236. Zhang, Y.; Liu, B.; Wu, X.; Li, R.; Tang, Z.; Ge, Z.; Li, R.; Yin, Y. New pyridin-3-ylmethyl carbamothioic esters activate pyruvate kinase M2 and potential anticancer lead compounds. Bioorg. Med. Chem. 2015, 23, 4815–4823. [CrossRef]

237. Li, Y.; Bao, M.; Yang, C.; Chen, J.; Zhou, S.; Sun, R.; Wu, C.; Li, X.; Bao, J. Computer-aided identification of a novel pyruvate kinase M2 activator compound. Cell Prolif. 2018, 51, e12509. [CrossRef]

238. Li, R.Z.; Fan, X.X.; Shi, D.F.; Zhu, G.Y.; Wang, Y.W.; Luo, L.X.; Pan, H.D.; Yao, X.J.; Leung, E.L.; Liu, L. Identification of a new pyruvate kinase M2 isofrom (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC). Chem. Biol. Drug Des. 2018, 92, 1851–1858. [CrossRef]

239. Aslan, E.; Guler, C.; Adem, S. In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2. J. Enzym. Inhib. Med. Chem. 2016, 31, 314–317. [CrossRef]

240. Goetze, K.; Walenta, S.; Ksiazkiewicz, M.; Kunz-Schughart, L.A.; Mueller-Klieser, W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int. J. Oncol. 2011, 39, 453–463. [CrossRef]

241. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [CrossRef] [PubMed]

242. Doherty, J.R.; Cleveland, J.L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Investig. 2013, 123, 3685–3692. [CrossRef] [PubMed]

243. Gallo, M.; Sapiro, L.; Spina, A.;Naviglio, D.; Calogero, A.; Naviglio, S. Lactic dehydrogenase and cancer: An overview. Front. Biosci.-Landmark 2015, 12, 1234–1249.

244. San-Millán, I.; Brooks, G.A. Reexaming cancer metabolism: Lactate production for carcinogenesis could be the first and explanation of the Warburg Effect. Carcinogenesis 2017, 38, 119–133. [CrossRef]

245. Pathria, G.; Scott, D.A.; Feng, Y.; Sang Lee, J.; Fujita, Y.; Zhang, G.; Sahu, A.D.; Ruppin, E.; Herlyn, M.; Osterman, A.L. Targeting the Warburg effect via LDHA inhibition engages ATF 4 signaling for cancer cell survival. EMBO J. 2018, 37, e99735. [CrossRef]

246. Wang, X.; Xu, L.; Wu, Q.; Liu, M.; Tang, F.; Cai, Y.; Fan, W.; Huang, H.; Gu, X. Inhibition of LDHA deliver potential anticancer performance in renal cell carcinoma. Urol. Int. 2017, 99, 237–244. [CrossRef]

247. Feng, Y.; Xiong, Y.; Qiao, T.; Li, X.; Jia, L.; Han, Y. Lactic dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018, 7, 6124–6136. [CrossRef]

248. Le, A.; Cooper, C.R.; Gouw, A.M.; Dinavahi, R.; Maitra, A.; Deck, L.M.; Royer, R.E.; Vander Jagt, D.L.; Semenza, G.L.; Dang, C.V. Inhibition of lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 2010, 9, 2037–2042. [CrossRef]

249. Farabegoli, F.; Vettriano, M.; Manerba, M.; Fiume, L.; Roberti, M.; Di Stefano, G. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharmacol. 2012, 729–738. [CrossRef]

250. Muramatsu, H.; Sumitomo, M.; Morinaga, S.; Kajikawa, K.; Kobayashi, I.; Nishikawa, G.; Kato, Y.; Watanabe, M.; Zennami, K.; Kanao, K. Targeting lactate dehydrogenase-A promotes docetaxel-induced cytotoxicity predominantly in castration-resistant prostate cancer cells. Oncol. Rep. 2019, 42, 224–230. [CrossRef]

251. Zhou, M.; Zhao, Y.; Ding, Y.; Liu, H.; Liu, Z.; Fodstad, O.; Riker, A.I.; Kamarajugadda, S.; Lu, J.; Owen, L.B. Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 2010, 9, 33. [CrossRef]

252. Yu, H.; Yin, Y.; Yi, Y.; Cheng, Z.; Kuang, W.; Li, R.; Zhong, H.; Cui, Y.; Yuan, L.; Gong, F. Targeting lactate dehydrogenase A (LDHA) exerts antileukemic effects on T-cell acute lymphoblastic leukemia. Cancer Commun. 2020, 40, 501–517. [CrossRef]

253. Koukourakis, M.; Tsolou, A.; Pouliiliou, S.; Lamprou, I.; Papadopoulou, M.; Ilemosoglou, M.; Kostoglou, G.; Ananiadou, D.; Sivridis, E.; Giatromanolaki, A. Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. Biochem. Biophys. Res. Commun. 2017, 491, 932–938. [CrossRef]

254. Altinoz, M.A.; Ozpinar, A. Oxamate targeting aggressive cancers with special emphasis to brain tumors. Bioimed. Pharmacother. 2022, 147, 112686. [CrossRef]

255. Yang, X.; Lu, Y.; Hang, J.; Zhang, J.; Zhang, T.; Huo, Y.; Liu, J.; Lai, S.; Luo, D.; Wang, L. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radiosensitivity of Pancreatic Cancer Lactate-Activated MDSCs Promote Radiosensitivity in PDAC. Cancer Immunol. Res. 2020, 8, 1440–1451. [CrossRef]

256. Maffouh, M.; Avan, A.; Sciarillo, R.; Granchi, C.; Leon, L.; Rani, R.; Funel, N.; Smid, K.; Honeywell, R.; Boggi, U. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br. J. Cancer 2014, 110, 172–182. [CrossRef]

257. Kim, E.-Y.; Chung, T.-W.; Han, C.W.; Park, S.Y.; Park, K.H.; Jang, S.B.; Ha, K.-T. A novel lactate dehydrogenase inhibitor, 1-(phenylseleno)-4-(trifluoromethyl) benzene, suppresses tumor growth through apoptotic cell death. Sci. Rep. 2019, 9, 3969. [CrossRef]

258. Schwab, M.; Thunborg, K.; Azimzadeh, O.; von Toerne, C.; Werner, C.; Shvetsov, M.; Di Genio, T.; Zdralovic, M.; Pouyssegur, J.; Renner, K. Targeting cancer metabolism breaks radiosensitivity by impairing the stress response. Cancers 2021, 13, 3762. [CrossRef]

259. Fu, D.; Li, J.; Wei, J.; Zhang, Z.; Luo, Y.; Tan, H.; Ren, C. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell Commun. Signal. 2018, 16, 8. [CrossRef]
260. Hu, H.; Juvekar, A.; Lyssiotis, C.A.; Lien, E.C.; Albeck, J.G.; Oh, D.; Varma, G.; Hung, Y.P.; Ullas, S.; Lauring, J. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 2016, 164, 433–446. [CrossRef]

261. Li, X.; Jiang, F.; Ge, Z.; Chen, B.; Yu, J.; Xin, M.; Wang, J.; An, L.; Wei, J.; Wu, L. Fructose-bisphosphatase aldolase a regulates hypoxic adaptation in hepatocellular carcinoma and involved with tumor malignancy. Dig. Dis. Sci. 2019, 64, 3215–3227. [CrossRef]

262. Ma, D.; Chen, X.; Zhang, P.; Zhang, H.; Wei, L.; Hu, S.; Tang, J.; Zhou, M.; Xie, C.; Ou, R. Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth. Oncogene 2018, 37, 1041–1048. [CrossRef]

263. Grandjean, G.; de Jong, P.R.; James, B.P.; Koh, M.Y.; Lemos, R.; Kingston, J.; Aleshin, A.; Bankston, L.A.; Miller, C.P.; Cho, E.J. Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Targeting a Glycolysis HIF-1 Feed-Forward Loop. Cancer Res. 2016, 76, 4259–4269. [CrossRef]

264. Chang, Y.-C.; Chou, J.; Yang, Y.-F.; Su, C.-Y.; Lin, Y.-F.; Yang, C.-N.; Lu, P.-J.; Huang, M.-S.; Yang, C.-J.; Hsiao, M. Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival. Targeting of ALDOA Inhibits Lung Cancer Metastasis. Cancer Res. 2019, 79, 4754–4766. [CrossRef]

265. Yu, T.; Zhao, Y.; Hu, Z.; Li, J.; Chu, D.; Zhang, J.; Li, Z.; Chen, B.; Zhang, X.; Pan, H. MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated mTOR Pathway. MetaLnc9 Interacts with PGK1 and NONO in NSCLC. Cancer Res. 2017, 77, 5782–5794. [CrossRef]

266. Huang, B.; Cai, W.; Wang, Q.; Liu, F.; Xu, M.; Zhang, Y. Gankyrin drives malignant transformation of gastric cancer and alleviates oxidative stress via mTORC1 activation. Oxid. Med. Cell. Longev. 2018, 2018, 9480316. [CrossRef]

267. Hu, H.; Zhu, W.; Qin, J.; Chen, M.; Gong, L.; Li, L.; Liu, X.; Tao, Y.; Yin, H.; Zhou, H.; et al. Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hепatology 2017, 65, 515–528. [CrossRef] [PubMed]

268. He, Y.; Luo, Y.; Zhang, D.; Wang, X.; Zhang, P.; Li, H.; Ejaz, S.; Liang, S.; Peng, X.; Gong, F.; Chen, Y.; Qiu, M.; Cheng, K.; Tang, J.; Ge, J.; Chen, N.; Zeng, H.; Liu, J. Proteomics identification of PGAM1 as a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer 2010, 9, 81. [CrossRef] [PubMed]

269. Ren, F.; Wu, H.; Lei, Y.; Zhang, H.; Liu, R.; Zhao, Y.; Chen, X.; Zeng, D.; Tong, A.; Chen, L. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol. Cancer 2016, 15, 22. [CrossRef]

270. Peng, X.; Gong, F.; Chen, Y.; Qiu, M.; Cheng, K.; Tang, J.; Ge, J.; Chen, N.; Zeng, H.; Liu, J. Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. J. Proteome. 2016, 132, 85–92. [CrossRef]

271. Chen, G.; Gharib, T.G.; Wang, H.; Huang, C.-C.; Kuick, R.; Thomas, D.G.; Shedden, K.A.; Misek, D.E.; Taylor, J.M.; Giordano, T.J. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012, 22, 585–600. [CrossRef]

272. He, Y.; Luo, Y.; Zhang, D.; Wang, X.; Zhang, P.; Li, H.; Ejaz, S.; Liang, S.; Peng, X.; Gong, F.; Chen, Y.; Qiu, M.; Cheng, K.; Tang, J.; Ge, J.; Chen, N.; Zeng, H.; Liu, J. Proteomics identification of PGAM1 as a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer 2010, 9, 81. [CrossRef] [PubMed]

273. Peng, X.; Gong, F.; Chen, Y.; Qiu, M.; Cheng, K.; Tang, J.; Ge, J.; Chen, N.; Zeng, H.; Liu, J. Proteome identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. J. Proteome. 2016, 132, 85–92. [CrossRef]

274. Chen, G.; Gharib, T.G.; Wang, H.; Huang, C.-C.; Kuick, R.; Thomas, D.G.; Shedden, K.A.; Misek, D.E.; Taylor, J.M.; Giordano, T.J. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2003, 100, 13537–13542. [CrossRef]

275. Evans, M.J.; Saghatelian, A.; Sorensen, E.J.; Cravatt, B.F. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 2005, 23, 1303–1307. [CrossRef]

276. Hitesugui, T.; Zhou, L.; Fan, J.; Elf, S.; Zhang, L.; Xie, J.; Wang, Y.; Gu, T.-L.; Alečković, M.; LeRoy, G. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat. Commun. 2013, 4, 1790. [CrossRef] [PubMed]

277. Ren, F.; Wu, H.; Lei, Y.; Zhang, H.; Liu, R.; Zhao, Y.; Chen, X.; Zeng, D.; Tong, A.; Chen, L. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol. Cancer 2010, 9, 81. [CrossRef] [PubMed]

278. Peng, X.; Gong, F.; Chen, Y.; Qiu, M.; Cheng, K.; Tang, J.; Ge, J.; Chen, N.; Zeng, H.; Liu, J. Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer. J. Proteome. 2016, 132, 85–92. [CrossRef]

279. Chan, A.K.; Bruce, J.I.; Siriwardena, A.K. Glucose metabolic phenotype of pancreatic cancer: its clinical and diagnostic significance. Gastroenterol. Res. Pract. 2018, 2018, 3842198. [CrossRef]

280. Qian, X.; Wu, W.; Xu, J.; Shu, Q.; Li, J.; Weng, Y.; Jiang, Z.; Feng, L.; Wang, X.; Zhou, J. Enolase 1 stimulates glycolysis to promote chemo-resistance in gastric cancer. Oncotarget 2017, 8, 47691. [CrossRef]

281. Scatena, R.; Bottino, P.; Pontoglio, A.; Mastrotaro, L.; Giardina, B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin. Investig. Drugs 2008, 17, 1533–1545. [CrossRef]

282. Chan, A.K.; Bruce, J.I.; Siriwardena, A.K. Glucose metabolic phenotype of pancreatic cancer. World J. Gastroenterol. 2016, 22, 3471. [CrossRef]

283. Muller, F.L.; Colla, S.; Aquilani, E.; Manzo, V.E.; Genovese, G.; Lee, J.; Eissendorf, R.; Deng, P.; Nezi, L. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 2012, 488, 337–342. [CrossRef]

284. Capello, M.; Ferri-Borgogno, S.; Riganti, C.; Chattaragada, M.S.; Principe, M.; Roux, C.; Zhou, W.; Petricoin, E.F.; Cappello, P.; Novelli, F. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget 2016, 7, 5598. [CrossRef] [PubMed]

285. Jung, D.-W.; Kim, W.-H.; Park, S.-H.; Lee, J.; Kim, J.; Su, D.; Ha, H.-H.; Chang, Y.-T.; Williams, D.R. A unique small molecule inhibitor of enolase clarifies its fundamental role in cellular processes. ACS Chem. Biol. 2013, 8, 1271–1282. [CrossRef] [PubMed]

286. Pinheiro, C.; Longatto-Filho, A.; Azevedo-Silva, J.; Casal, M.; Schmitt, F.C.; Baltazar, F. Role of monocarboxylate transporters in human cancers: State of the art. J. Bioenerg. Biomembr. 2012, 44, 127–139. [CrossRef] [PubMed]

287. Bola, B.M.; Chadwick, A.L.; Michopoulos, F.; Blount, K.G.; Telfer, B.A.; Williams, K.J.; Smith, P.D.; Critchlow, S.E.; Stratford, I.J. Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport.Inhibition of MCT1 Potentiates Radiotherapy. Mol. Cancer Ther. 2014, 13, 2805–2816. [CrossRef]
285. Beloueche-Babari, M.; Casals Galobart, T.; Delgado-Goni, T.; Wantuch, S.; Parkes, H.G.; Tandy, D.; Harker, J.A.; Leach, M.O. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br. J. Cancer 2020, 122, 895–903. [CrossRef]

286. Huang, T.; Feng, Q.; Wang, Z.; Li, W.; Sun, Z.; Wilhelm, J.; Huang, G.; Vo, T.; Sumer, B.D.; Gao, J. Tumor-Targeted Inhibition of Monocarboxylate Transporter 1 Improves T-Cell Immunotherapy of Solid Tumors. Adv. Healthc. Mater. 2021, 10, 2000549. [CrossRef]

287. Ždralević, M.; Vučetić, M.; Daher, B.; Marchiq, I.; Parks, S.K.; Pouysségur, J. Disrupting the ‘Warburg effect’-routes cancer cells to OXPHOS offering a vulnerability point via ‘ferroptosis’-induced cell death. Adv. Biol. Regul. 2018, 68, 55–63. [CrossRef]

288. Draoui, N.; Schicke, O.; Seront, E.; Bouzin, C.; Sonveaux, P.; Riant, O.; Feron, O. Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol. Cancer Ther. 2014, 13, 1410–1418. [CrossRef]

289. Pertega-Gomes, N.; Felisbino, S.; Massie, C.E.; Vizcaino, J.R.; Coelho, R.; Sandi, C.; Simeo-Sousa, S.; Jurmeister, S.; Ramos-Montoya, A.; Asim, M. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for monocarboxylate transporters as metabolic targets for therapy. J. Pathol. 2015, 236, 517–530. [CrossRef]

290. Fang, Y.; Liu, W.; Tang, Z.; Ji, X.; Zhou, Y.; Song, S.; Tian, M.; Tao, C.; Huang, R.; Zhu, G. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology 2022. [CrossRef]

291. Metallo, C.M.; Gameiro, P.A.; Bell, E.L.; Mattaini, K.R.; Yang, J.; Hiller, K.; Jewell, C.M.; Johnson, Z.R.; Irvine, D.J.; Guarente, L. Simultaneous Targeting of Monocarboxylate Transporter 1 and 3 Improves T Cell Function in Oncolytic HIV-1. Cancer Sci. 2018, 109, 1286–1294. [CrossRef]

292. Waitkus, M.S.; Diplas, B.H.; Yan, H. Biological role and therapeutic potential of IDH mutations in cancer. Cell. 2014, 157, 1037–1052. [PubMed]

293. Romanidou, O.; Kotoula, V.; Fountzilas, G. Bridging cancer biology with the clinic: Comprehending and exploiting IDH gene mutations in gliomas. Cancer Genom. Proteom. 2018, 15, 186–195. [CrossRef] [PubMed]

294. Rohle, D.; Popovic-Muller, J.; Palaskas, N.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.; Komisopoulou, E. Acetate and lactate might work together in gliomas: A combined in vitro and in vivo study of mutant IDH1 and IDH2. Cell. Rep. 2019, 29, 1416–1427. [PubMed]

295. Gong, Y.; Ji, P.; Yang, Y.-S.; Xie, S.; Yu, T.; Song, Y.; Dang, C. High glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose. Biomed. Rep. 2019, 20, 293–300. [CrossRef]

296. Lapa, B.; Goncalves, A.C.; Jorge, J.; Alves, R.; Pires, A.S.; Abrantes, A.M.; Coucelo, M.; Abrunhosa, A.; Botelho, M.F.; Nascimento-Costa, J.M.; et al. Acute myeloid leukemia sensitivity to metabolic inhibitors: Glycolysis showed to be a better therapeutic target. Med. Oncol. 2020, 37, 72. [CrossRef]

297. Zdralevic, M.; Brand, A.; Di Ianni, L.; Dettmer, K.; Reinders, J.; Singer, K.; Peter, K.; Schnell, A.; Bruss, C.; Decking, S.M.; et al. Double genetic disruption of lactate dehydrogenases A and B is required to ablate the "Warburg effect" restricting tumor growth to oxidative metabolism. J. Biol. Chem. 2018, 293, 15947–15961. [CrossRef]

298. Zhou, Y.; Guo, Y.; Tam, K.Y. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents. Expert. Opin. Ther. Pat. 2022, 32, 441–453. [CrossRef]

299. Korga, A.; Ostrowska, M.; Jozefczyk, A.; Iwan, M.; Wojcik, R.; Zgorka, G.; Herbet, M.; Vilarrubla, G.G.; Dudka, J. Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells. J. Cell. Mol. Med. 2019, 23, 22. [CrossRef]

300. Zhang, D.; Li, J.; Wang, F.; Hu, J.; Wang, S.; Sun, Y.; Xiao, Y.; Jin, M.-L.; Ma, D.; Guo, L.-W.; Pei, Y.-C. Metabolic-pathway-based subtyping of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose. Oncol. Rep. 2012, 27, 347–355. [CrossRef]

301. Cheng, Y.; Xiao, Y.; Zeng, Q.; Sun, B.; Song, Y.; Yu, T.; Chen, X.; Jin, M.-L.; Ma, D.; Guo, L.-W.; Wei, Y.-C. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021, 33, 51–64.e9. [CrossRef]

302. Zhang, T.; Zhu, X.; Wu, H.; Jiang, K.; Zhao, G.; Shaukat, A.; Deng, G.; Qiu, C. Targeting the ROS/PI3K/AKT/HIF-1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose. J. Cell. Mol. Med. 2019, 23, 3711–3723. [CrossRef]

303. Takemura, A.; Che, X.-F.; Tabuchi, T.; Moriya, S.; Miyazawa, K.; Tomoda, A. Enhancement of cytotoxic and pro-apoptotic effects of 2-amino-phenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose. Oncol. Rep. 2012, 27, 347–355. [PubMed]
309. Hui, S.; Ghergurovich, J.M.; Morscher, R.J.; Jang, C.; Teng, X.; Lu, W.; Esparza, L.A.; Reya, T.; Zhan, L.; Yanxiang Guo, J. Glucose feeds the TCA cycle via circulating lactate. *Nature* 2017, 551, 115–118. [CrossRef]

310. Chaube, B.; Malvi, P.; Singh, S.V.; Mohammad, N.; Meena, A.S.; Bhat, M.K. Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. *Oncotarget* 2015, 6, 37281. [CrossRef]

311. O’Neill, L.A.; Kishton, R.J.; Rathmell, J. A guide to immunometabolism for immunologists. *Nat. Rev. Immunol.* 2016, 16, 553–565. [CrossRef] [PubMed]

312. O’Sullivan, D.; Sanin, D.E.; Pearce, E.J.; Pearce, E.L. Metabolic interventions in the immune response to cancer. *Nat. Rev. Immunol.* 2019, 19, 324–335. [CrossRef] [PubMed]

313. Li, X.; Wenes, M.; Romero, P.; Huang, S.C.-C.; Fendt, S.-M.; Ho, P.-C. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. *Nat. Rev. Clin. Oncol.* 2019, 16, 425–441. [CrossRef] [PubMed]